1
|
Zhang Z, Jiang H, Jiang S, Dong T, Wang X, Wang Y, Li Y. Rapid Detection of the Monkeypox Virus Genome and Antigen Proteins Based on Surface-Enhanced Raman Spectroscopy. ACS Appl Mater Interfaces 2023; 15:34419-34426. [PMID: 37436060 DOI: 10.1021/acsami.3c04285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/13/2023]
Abstract
The conventional detection methods cannot satisfy the need for early and rapid detection of monkeypox virus (MPXV) infection. This is due to complicated pretreatment, time consumption, and complex operation of the diagnostic tests. Based on surface-enhanced Raman spectroscopy (SERS), this study attempted to capture the characteristic fingerprints of the MPXV genome and multiple antigenic proteins without the need to design specific probes. The minimum detection limit of this method is 100 copies/mL, with good reproducibility and signal-to-noise ratio. Therefore, the relationship between characteristic peak intensity and the protein and nucleic acid concentration can be used to construct a concentration-dependent spectral line with a good linear relationship. Additionally, principal component analysis (PCA) could identify the SERS spectra of four different MPXV proteins in serum. Therefore, this rapid detection method in the current outbreak of monkeypox control and the future response to possible new outbreaks has broad application prospects.
Collapse
Affiliation(s)
- Zhe Zhang
- State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), College of Pharmacy, Harbin Medical University, Baojian Road No. 157, Harbin 150081, Heilongjiang, China
| | - Heng Jiang
- College of Public Health, Harbin Medical University, Baojian Road No. 157, Harbin 150081, Heilongjiang, China
| | - Shen Jiang
- State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), College of Pharmacy, Harbin Medical University, Baojian Road No. 157, Harbin 150081, Heilongjiang, China
| | - Tuo Dong
- College of Public Health, Harbin Medical University, Baojian Road No. 157, Harbin 150081, Heilongjiang, China
| | - Xiaotong Wang
- State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), College of Pharmacy, Harbin Medical University, Baojian Road No. 157, Harbin 150081, Heilongjiang, China
| | - Yunpeng Wang
- State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), College of Pharmacy, Harbin Medical University, Baojian Road No. 157, Harbin 150081, Heilongjiang, China
| | - Yang Li
- State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), College of Pharmacy, Harbin Medical University, Baojian Road No. 157, Harbin 150081, Heilongjiang, China
- Research Unit of Health Sciences and Technology (HST), Faculty of Medicine, University of Oulu, Oulu 90220, Finland
- Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province), College of Pharmacy, Harbin Medical University, Harbin 150081, China
| |
Collapse
|
2
|
Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, Walt DR. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. Clin Infect Dis 2023; 76:e487-e490. [PMID: 36052466 PMCID: PMC10169416 DOI: 10.1093/cid/ciac722] [Citation(s) in RCA: 147] [Impact Index Per Article: 147.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2022] [Revised: 08/25/2022] [Accepted: 08/30/2022] [Indexed: 02/02/2023] Open
Abstract
The diagnosis of postacute sequelae of coronavirus disease 2019 (PASC) poses an ongoing medical challenge. To identify biomarkers associated with PASC we analyzed plasma samples collected from PASC and coronavirus disease 2019 patients to quantify viral antigens and inflammatory markers. We detect severe acute respiratory syndrome coronavirus 2 spike predominantly in PASC patients up to 12 months after diagnosis.
Collapse
Affiliation(s)
- Zoe Swank
- Harvard Medical School, Boston, Massachusetts, USA
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA
| | - Yasmeen Senussi
- Harvard Medical School, Boston, Massachusetts, USA
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA
| | | | - Xu G Yu
- Harvard Medical School, Boston, Massachusetts, USA
- Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA
- Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Jonathan Z Li
- Harvard Medical School, Boston, Massachusetts, USA
- Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Galit Alter
- Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - David R Walt
- Harvard Medical School, Boston, Massachusetts, USA
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA
| |
Collapse
|
3
|
Perkins TA, Stephens M, Alvarez Barrios W, Cavany S, Rulli L, Pfrender ME. Performance of Three Tests for SARS-CoV-2 on a University Campus Estimated Jointly with Bayesian Latent Class Modeling. Microbiol Spectr 2022; 10:e0122021. [PMID: 35044220 PMCID: PMC8768831 DOI: 10.1128/spectrum.01220-21] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Accepted: 12/12/2021] [Indexed: 12/19/2022] Open
Abstract
Accurate tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been critical in efforts to control its spread. The accuracy of tests for SARS-CoV-2 has been assessed numerous times, usually in reference to a gold standard diagnosis. One major disadvantage of that approach is the possibility of error due to inaccuracy of the gold standard, which is especially problematic for evaluating testing in a real-world surveillance context. We used an alternative approach known as Bayesian latent class modeling (BLCM), which circumvents the need to designate a gold standard by simultaneously estimating the accuracy of multiple tests. We applied this technique to a collection of 1,716 tests of three types applied to 853 individuals on a university campus during a 1-week period in October 2020. We found that reverse transcriptase PCR (RT-PCR) testing of saliva samples performed at a campus facility had higher sensitivity (median, 92.3%; 95% credible interval [CrI], 73.2 to 99.6%) than RT-PCR testing of nasal samples performed at a commercial facility (median, 85.9%; 95% CrI, 54.7 to 99.4%). The reverse was true for specificity, although the specificity of saliva testing was still very high (median, 99.3%; 95% CrI, 98.3 to 99.9%). An antigen test was less sensitive and specific than both of the RT-PCR tests, although the sample sizes with this test were small and the statistical uncertainty was high. These results suggest that RT-PCR testing of saliva samples at a campus facility can be an effective basis for surveillance screening to prevent SARS-CoV-2 transmission in a university setting. IMPORTANCE Testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been vitally important during the COVID-19 pandemic. There are a variety of methods for testing for this virus, and it is important to understand their accuracy in choosing which one might be best suited for a given application. To estimate the accuracy of three different testing methods, we used a data set collected at a university that involved testing the same samples with multiple tests. Unlike most other estimates of test accuracy, we did not assume that one test was perfect but instead allowed for some degree of inaccuracy in all testing methods. We found that molecular tests performed on saliva samples at a university facility were similarly accurate as molecular tests performed on nasal samples at a commercial facility. An antigen test appeared somewhat less accurate than the molecular tests, but there was high uncertainty about that.
Collapse
Affiliation(s)
- T. Alex Perkins
- Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, USA
| | - Melissa Stephens
- Genomics and Bioinformatics Core Facility, University of Notre Dame, Notre Dame, Indiana, USA
| | | | - Sean Cavany
- Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, USA
| | - Liz Rulli
- Notre Dame Research, University of Notre Dame, Notre Dame, Indiana, USA
| | - Michael E. Pfrender
- Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, USA
| |
Collapse
|
4
|
Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky U, Brown SM, Knowlton KU, Self WH, Files DC, Jain MK, Benfield T, Bowdish ME, Leshnower BG, Baker JV, Jensen JU, Gardner EM, Ginde AA, Harris ES, Johansen IS, Markowitz N, Matthay MA, Østergaard L, Chang CC, Goodman AL, Chang W, Dewar RL, Gerry NP, Higgs ES, Highbarger H, Murray DD, Murray TA, Natarajan V, Paredes R, Parmar MKB, Phillips AN, Reilly C, Rupert AW, Sharma S, Shaw-Saliba K, Sherman BT, Teitelbaum M, Wentworth D, Cao H, Klekotka P, Babiker AG, Davey VJ, Gelijns AC, Kan VL, Polizzotto MN, Thompson BT, Lane HC, Neaton JD. Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial. Ann Intern Med 2022; 175:234-243. [PMID: 34928698 PMCID: PMC9334931 DOI: 10.7326/m21-3507] [Citation(s) in RCA: 29] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND In a randomized, placebo-controlled, clinical trial, bamlanivimab, a SARS-CoV-2-neutralizing monoclonal antibody, given in combination with remdesivir, did not improve outcomes among hospitalized patients with COVID-19 based on an early futility assessment. OBJECTIVE To evaluate the a priori hypothesis that bamlanivimab has greater benefit in patients without detectable levels of endogenous neutralizing antibody (nAb) at study entry than in those with antibodies, especially if viral levels are high. DESIGN Randomized, placebo-controlled trial. (ClinicalTrials.gov: NCT04501978). SETTING Multicenter trial. PATIENTS Hospitalized patients with COVID-19 without end-organ failure. INTERVENTION Bamlanivimab (7000 mg) or placebo. MEASUREMENTS Antibody, antigen, and viral RNA levels were centrally measured on stored specimens collected at baseline. Patients were followed for 90 days for sustained recovery (defined as discharge to home and remaining home for 14 consecutive days) and a composite safety outcome (death, serious adverse events, organ failure, or serious infections). RESULTS Among 314 participants (163 receiving bamlanivimab and 151 placebo), the median time to sustained recovery was 19 days and did not differ between the bamlanivimab and placebo groups (subhazard ratio [sHR], 0.99 [95% CI, 0.79 to 1.22]; sHR > 1 favors bamlanivimab). At entry, 50% evidenced production of anti-spike nAbs; 50% had SARS-CoV-2 nucleocapsid plasma antigen levels of at least 1000 ng/L. Among those without and with nAbs at study entry, the sHRs were 1.24 (CI, 0.90 to 1.70) and 0.74 (CI, 0.54 to 1.00), respectively (nominal P for interaction = 0.018). The sHR (bamlanivimab vs. placebo) was also more than 1 for those with plasma antigen or nasal viral RNA levels above median level at entry and was greatest for those without antibodies and with elevated levels of antigen (sHR, 1.48 [CI, 0.99 to 2.23]) or viral RNA (sHR, 1.89 [CI, 1.23 to 2.91]). Hazard ratios for the composite safety outcome (<1 favors bamlanivimab) also differed by serostatus at entry: 0.67 (CI, 0.37 to 1.20) for those without and 1.79 (CI, 0.92 to 3.48) for those with nAbs. LIMITATION Subgroup analysis of a trial prematurely stopped because of futility; small sample size; multiple subgroups analyzed. CONCLUSION Efficacy and safety of bamlanivimab may differ depending on whether an endogenous nAb response has been mounted. The limited sample size of the study does not allow firm conclusions based on these findings, and further independent trials are required that assess other types of passive immune therapies in the same patient setting. PRIMARY FUNDING SOURCE U.S. government Operation Warp Speed and National Institute of Allergy and Infectious Diseases.
Collapse
MESH Headings
- Adenosine Monophosphate/adverse effects
- Adenosine Monophosphate/analogs & derivatives
- Adenosine Monophosphate/therapeutic use
- Aged
- Alanine/adverse effects
- Alanine/analogs & derivatives
- Alanine/therapeutic use
- Antibodies, Monoclonal, Humanized/adverse effects
- Antibodies, Monoclonal, Humanized/therapeutic use
- Antibodies, Neutralizing/adverse effects
- Antibodies, Neutralizing/blood
- Antibodies, Neutralizing/therapeutic use
- Antigens, Viral/blood
- Antiviral Agents/adverse effects
- Antiviral Agents/therapeutic use
- Biomarkers/blood
- COVID-19/blood
- COVID-19/virology
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Humans
- Male
- Medical Futility
- Middle Aged
- RNA, Viral/blood
- SARS-CoV-2
- Treatment Failure
- COVID-19 Drug Treatment
Collapse
Affiliation(s)
- Jens D Lundgren
- CHIP Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark
| | - Birgit Grund
- Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota
| | - Christina E Barkauskas
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University, Durham, North Carolina
| | - Thomas L Holland
- Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina
| | | | | | - Samuel M Brown
- Intermountain Medical Center, Murray, and University of Utah, Salt Lake City, Utah
| | | | - Wesley H Self
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - D Clark Files
- Section on Pulmonary, Critical Care, Allergy, and Immunology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - Mamta K Jain
- University of Texas Southwestern Medical Center, Dallas, Texas
| | - Thomas Benfield
- Department of Infectious Diseases, Hvidovre and Amager Hospital, University of Copenhagen, Hvidovre, Denmark
| | - Michael E Bowdish
- Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California
| | - Bradley G Leshnower
- Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Georgia
| | - Jason V Baker
- Hennepin Healthcare Research Institute and University of Minnesota, Minneapolis, Minnesota
| | - Jens-Ulrik Jensen
- CHIP Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, and Respiratory Medicine Section, Department of Internal Medicine, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
| | - Edward M Gardner
- Denver Public Health, Denver Health and Hospital Authority, Denver, Colorado
| | - Adit A Ginde
- Department of Emergency Medicine, School of Medicine, University of Colorado, Aurora, Colorado
| | | | - Isik S Johansen
- Department of Infectious Diseases, Odense University Hospital, Odense, Denmark
| | - Norman Markowitz
- Department of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan
| | - Michael A Matthay
- Department of Medicine and Department of Anesthesia and Cardiovascular Research Institute, The University of California, San Francisco, San Francisco, California
| | | | - Christina C Chang
- The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
| | - Anna L Goodman
- Medical Research Council Clinical Trials Unit at University College London and Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom
| | - Weizhong Chang
- Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, Maryland
| | | | - Norman P Gerry
- Advanced Biomedical Laboratories, Cinnaminson, New Jersey
| | - Elizabeth S Higgs
- National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
| | - Helene Highbarger
- Leidos Biomedical Research and AIDS Monitoring Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland
| | - Daniel D Murray
- CHIP Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark
| | - Thomas A Murray
- Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota
| | - Ven Natarajan
- Laboratory of Molecular Cell Biology, Frederick National Laboratory for Cancer Research, Frederick, Maryland
| | - Roger Paredes
- Infectious Diseases Department and IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - Mahesh K B Parmar
- Medical Research Council Clinical Trials Unit and Institute of Clinical Trials and Methodology at University College London, London, United Kingdom
| | - Andrew N Phillips
- Institute for Global Health, University College London, London, United Kingdom
| | - Cavan Reilly
- Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota
| | - Adam W Rupert
- AIDS Monitoring Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland
| | - Shweta Sharma
- Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota
| | | | - Brad T Sherman
- Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, Maryland
| | | | - Deborah Wentworth
- Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota
| | - Huyen Cao
- Gilead Sciences, Foster City, California
| | | | - Abdel G Babiker
- Medical Research Council Clinical Trials Unit at University College London, London, United Kingdom
| | | | - Annetine C Gelijns
- Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Virginia L Kan
- Veterans Affairs Medical Center and School of Medicine and Health Sciences, George Washington University, Washington, DC
| | - Mark N Polizzotto
- The Kirby Institute, University of New South Wales, and St Vincent's Hospital, Sydney, New South Wales, Australia
| | - B Taylor Thompson
- Division of Pulmonary and Critical Care, Department of Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts
| | - H Clifford Lane
- National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
| | - James D Neaton
- Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota
| |
Collapse
|
5
|
Martin‐Vicente M, Almansa R, Martínez I, Tedim AP, Bustamante E, Tamayo L, Aldecoa C, Gómez JM, Renedo G, Berezo JÁ, Cedeño JA, Mamolar N, García Olivares P, Herrán‐Monge R, Cicuendez R, Enríquez P, Ortega A, Jorge N, Doncel C, de la Fuente A, Bustamante‐Munguira J, Muñoz‐Gómez MJ, González‐Rivera M, Puertas C, Más V, Vázquez M, Pérez‐García F, Rico‐Feijoo J, Martín S, Motos A, Fernandez‐Barat L, Eiros JM, Dominguez‐Gil M, Ferrer R, Barbé F, Trapiello W, Kelvin DJ, Bermejo‐Martin JF, Resino S, Torres A. Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients. J Intern Med 2022; 291:232-240. [PMID: 34611927 PMCID: PMC8661581 DOI: 10.1111/joim.13386] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND Anti-SARS-CoV-2 S antibodies prevent viral replication. Critically ill COVID-19 patients show viral material in plasma, associated with a dysregulated host response. If these antibodies influence survival and viral dissemination in ICU-COVID patients is unknown. PATIENTS/METHODS We studied the impact of anti-SARS-CoV-2 S antibodies levels on survival, viral RNA-load in plasma, and N-antigenaemia in 92 COVID-19 patients over ICU admission. RESULTS Frequency of N-antigenaemia was >2.5-fold higher in absence of antibodies. Antibodies correlated inversely with viral RNA-load in plasma, representing a protective factor against mortality (adjusted HR [CI 95%], p): (S IgM [AUC ≥ 60]: 0.44 [0.22; 0.88], 0.020); (S IgG [AUC ≥ 237]: 0.31 [0.16; 0.61], <0.001). Viral RNA-load in plasma and N-antigenaemia predicted increased mortality: (N1-viral load [≥2.156 copies/ml]: 2.25 [1.16; 4.36], 0.016); (N-antigenaemia: 2.45 [1.27; 4.69], 0.007). CONCLUSIONS Low anti-SARS-CoV-2 S antibody levels predict mortality in critical COVID-19. Our findings support that these antibodies contribute to prevent systemic dissemination of SARS-CoV-2.
Collapse
Affiliation(s)
- María Martin‐Vicente
- Unidad de Infección Viral e InmunidadCentro Nacional de MicrobiologíaInstituto de Salud Carlos IIIMajadahondaSpain
| | - Raquel Almansa
- Group for Biomedical Research in Sepsis (BioSepsis)Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de SaludSalamancaSpain
- Hospital Universitario Río HortegaGerencia Regional de SaludValladolidSpain
- Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES)Instituto de Salud Carlos IIIMadridSpain
| | - Isidoro Martínez
- Unidad de Infección Viral e InmunidadCentro Nacional de MicrobiologíaInstituto de Salud Carlos IIIMajadahondaSpain
| | - Ana P. Tedim
- Group for Biomedical Research in Sepsis (BioSepsis)Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de SaludSalamancaSpain
- Hospital Universitario Río HortegaGerencia Regional de SaludValladolidSpain
| | - Elena Bustamante
- Group for Biomedical Research in Sepsis (BioSepsis)Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de SaludSalamancaSpain
- Intensive Care UnitHospital Clínico Universitario de Valladolid, Gerencia Regional de SaludValladolidSpain
| | - Luis Tamayo
- Group for Biomedical Research in Sepsis (BioSepsis)Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de SaludSalamancaSpain
- Intensive Care UnitHospital Universitario Rio Hortega, Gerencia Regional de SaludValladolidSpain
| | - César Aldecoa
- Group for Biomedical Research in Sepsis (BioSepsis)Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de SaludSalamancaSpain
- Department of AnesthesiologyFacultad de Medicina de ValladolidValladolidSpain
- Anesthesiology and Reanimation ServiceHospital Universitario Rio Hortega, Gerencia Regional de SaludValladolidSpain
| | - José Manuel Gómez
- Intensive Care Unit. Hospital General Universitario Gregorio Marañón, Calle del Dr. EsquerdoMadridSpain
| | - Gloria Renedo
- Intensive Care UnitHospital Clínico Universitario de Valladolid, Gerencia Regional de SaludValladolidSpain
| | - Jose Ángel Berezo
- Group for Biomedical Research in Sepsis (BioSepsis)Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de SaludSalamancaSpain
- Intensive Care UnitHospital Universitario Rio Hortega, Gerencia Regional de SaludValladolidSpain
| | - Jamil Antonio Cedeño
- Intensive Care Unit. Hospital General Universitario Gregorio Marañón, Calle del Dr. EsquerdoMadridSpain
| | - Nuria Mamolar
- Intensive Care UnitHospital Clínico Universitario de Valladolid, Gerencia Regional de SaludValladolidSpain
| | - Pablo García Olivares
- Intensive Care Unit. Hospital General Universitario Gregorio Marañón, Calle del Dr. EsquerdoMadridSpain
| | - Rubén Herrán‐Monge
- Group for Biomedical Research in Sepsis (BioSepsis)Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de SaludSalamancaSpain
- Intensive Care UnitHospital Universitario Rio Hortega, Gerencia Regional de SaludValladolidSpain
| | - Ramón Cicuendez
- Intensive Care UnitHospital Clínico Universitario de Valladolid, Gerencia Regional de SaludValladolidSpain
| | - Pedro Enríquez
- Group for Biomedical Research in Sepsis (BioSepsis)Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de SaludSalamancaSpain
- Intensive Care UnitHospital Universitario Rio Hortega, Gerencia Regional de SaludValladolidSpain
| | - Alicia Ortega
- Group for Biomedical Research in Sepsis (BioSepsis)Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de SaludSalamancaSpain
- Hospital Universitario Río HortegaGerencia Regional de SaludValladolidSpain
| | - Noelia Jorge
- Group for Biomedical Research in Sepsis (BioSepsis)Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de SaludSalamancaSpain
- Hospital Universitario Río HortegaGerencia Regional de SaludValladolidSpain
- Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES)Instituto de Salud Carlos IIIMadridSpain
| | - Cristina Doncel
- Group for Biomedical Research in Sepsis (BioSepsis)Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de SaludSalamancaSpain
- Hospital Universitario Río HortegaGerencia Regional de SaludValladolidSpain
- Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES)Instituto de Salud Carlos IIIMadridSpain
| | - Amanda de la Fuente
- Group for Biomedical Research in Sepsis (BioSepsis)Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de SaludSalamancaSpain
- Hospital Universitario Río HortegaGerencia Regional de SaludValladolidSpain
| | - Juan Bustamante‐Munguira
- Department of Cardiovascular SurgeryHospital Clínico Universitario de Valladolid, Gerencia Regional de SaludValladolidSpain
| | - María José Muñoz‐Gómez
- Unidad de Infección Viral e InmunidadCentro Nacional de MicrobiologíaInstituto de Salud Carlos IIIMajadahondaSpain
| | | | - Carolina Puertas
- Department of Laboratory MedicineHospital General Universitario Gregorio MarañónMadridSpain
| | - Vicente Más
- Unidad de Biología ViralCentro Nacional de MicrobiologíaInstituto de Salud Carlos IIIMadridSpain
| | - Mónica Vázquez
- Unidad de Biología ViralCentro Nacional de MicrobiologíaInstituto de Salud Carlos IIIMadridSpain
| | - Felipe Pérez‐García
- Servicio de Microbiología ClínicaHospital Universitario Príncipe de AsturiasMadridSpain
| | - Jesús Rico‐Feijoo
- Group for Biomedical Research in Sepsis (BioSepsis)Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de SaludSalamancaSpain
- Anesthesiology and Reanimation ServiceHospital Universitario Rio Hortega, Gerencia Regional de SaludValladolidSpain
| | - Silvia Martín
- Group for Biomedical Research in Sepsis (BioSepsis)Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de SaludSalamancaSpain
- Anesthesiology and Reanimation ServiceHospital Universitario Rio Hortega, Gerencia Regional de SaludValladolidSpain
| | - Anna Motos
- Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES)Instituto de Salud Carlos IIIMadridSpain
- Department of PulmonologyHospital Clinic de BarcelonaUniversidad de BarcelonaInstitut D investigacions August Pi I Sunyer (IDIBAPS)BarcelonaSpain
| | - Laia Fernandez‐Barat
- Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES)Instituto de Salud Carlos IIIMadridSpain
- Department of PulmonologyHospital Clinic de BarcelonaUniversidad de BarcelonaInstitut D investigacions August Pi I Sunyer (IDIBAPS)BarcelonaSpain
| | - Jose María Eiros
- Microbiology ServiceHospital Universitario Río Hortega, Gerencia Regional de SaludValladolidSpain
| | - Marta Dominguez‐Gil
- Microbiology ServiceHospital Universitario Río Hortega, Gerencia Regional de SaludValladolidSpain
| | - Ricard Ferrer
- Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES)Instituto de Salud Carlos IIIMadridSpain
- Intensive Care DepartmentVall d'Hebron Hospital Universitari, SODIR Research GroupVall d'Hebron Institut de RecercaBarcelonaSpain
| | - Ferrán Barbé
- Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES)Instituto de Salud Carlos IIIMadridSpain
- Respiratory DepartmentInstitut Ricerca Biomedica de LleidaLleidaSpain
| | - Wysali Trapiello
- Clinical Analysis ServiceHospital Clínico Universitario de Valladolid, Gerencia Regional de SaludValladolidSpain
| | - David J. Kelvin
- Department of Microbiology and ImmunologyFaculty of MedicineCanadian Center for Vaccinology CCfVDalhousie UniversityHalifaxNova ScotiaCanada
- Laboratory of ImmunityShantou University Medical CollegeShantouGuangdongChina
| | - Jesús F. Bermejo‐Martin
- Group for Biomedical Research in Sepsis (BioSepsis)Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de SaludSalamancaSpain
- Hospital Universitario Río HortegaGerencia Regional de SaludValladolidSpain
- Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES)Instituto de Salud Carlos IIIMadridSpain
| | - Salvador Resino
- Unidad de Infección Viral e InmunidadCentro Nacional de MicrobiologíaInstituto de Salud Carlos IIIMajadahondaSpain
| | - Antoni Torres
- Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES)Instituto de Salud Carlos IIIMadridSpain
- Department of PulmonologyHospital Clinic de BarcelonaUniversidad de BarcelonaInstitut D investigacions August Pi I Sunyer (IDIBAPS)BarcelonaSpain
| |
Collapse
|
6
|
Affiliation(s)
- Paul K Drain
- From the Departments of Global Health and Medicine, University of Washington, Seattle
| |
Collapse
|
7
|
Amexo JX, Negoro M, Kuurdor EDM, Lartey BL, Sokejima S, Sugata K, Tonto PB, Taniguchi K. Molecular Epidemiology of Norovirus (NoV) Infection in Mie Prefecture: The Kinetics of Norovirus Antigenemia in Pediatric Patients. Viruses 2022; 14:v14020173. [PMID: 35215766 PMCID: PMC8880472 DOI: 10.3390/v14020173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2021] [Revised: 01/13/2022] [Accepted: 01/14/2022] [Indexed: 12/10/2022] Open
Abstract
Few studies have shown the presence of norovirus (NoV) RNA in blood circulation but there is no data on norovirus antigenemia. We examined both antigenemia and RNAemia from the sera of children with NoV infections and studied whether norovirus antigenemia is correlated with the levels of norovirus-specific antibodies and clinical severity of gastroenteritis. Both stool and serum samples were collected from 63 children admitted to Mie National Hospital with acute NoV gastroenteritis. Norovirus antigen and RNA were detected in sera by ELISA and real-time RT-PCR, respectively. NoV antigenemia was found in 54.8% (34/62) and RNAemia in 14.3% (9/63) of sera samples. Antigenemia was more common in the younger age group (0–2 years) than in the older age groups, and most patients were male. There was no correlation between stool viral load and norovirus antigen (NoV-Ag) levels (rs = −0.063; Cl −0.3150 to 0.1967; p = 0.6251). Higher levels of acute norovirus-specific IgG serum antibodies resulted in a lower antigenemia OD value (n = 61; r = −0.4258; CI −0.62 to −0.19; p = 0.0006). Norovirus antigenemia occurred more commonly in children under 2 years of age with NoV-associated acute gastroenteritis. The occurrence of antigenemia was not correlated with stool viral load or disease severity.
Collapse
Affiliation(s)
- Jennifer X. Amexo
- Department of Public Health and Occupational Medicine, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu-shi 514-8507, Japan; (E.D.-M.K.); (S.S.)
- Department of Clinical Research, National Hospital Organization, Mie National Hospital, Tsu-shi 514-0125, Japan; (M.N.); (K.S.); (P.B.T.)
- Correspondence: (J.X.A.); (K.T.)
| | - Manami Negoro
- Department of Clinical Research, National Hospital Organization, Mie National Hospital, Tsu-shi 514-0125, Japan; (M.N.); (K.S.); (P.B.T.)
| | - Elijah Deku-Mwin Kuurdor
- Department of Public Health and Occupational Medicine, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu-shi 514-8507, Japan; (E.D.-M.K.); (S.S.)
| | - Belinda L. Lartey
- Department of Electron Microscopy and Histopathology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra 00233, Ghana;
| | - Shigeru Sokejima
- Department of Public Health and Occupational Medicine, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu-shi 514-8507, Japan; (E.D.-M.K.); (S.S.)
- Epidemiology Centre for Disease Control and Prevention, Mie University Hospital, Tsu-shi 514-8507, Japan
| | - Ken Sugata
- Department of Clinical Research, National Hospital Organization, Mie National Hospital, Tsu-shi 514-0125, Japan; (M.N.); (K.S.); (P.B.T.)
| | - Prince Baffour Tonto
- Department of Clinical Research, National Hospital Organization, Mie National Hospital, Tsu-shi 514-0125, Japan; (M.N.); (K.S.); (P.B.T.)
| | - Kiyosu Taniguchi
- Department of Clinical Research, National Hospital Organization, Mie National Hospital, Tsu-shi 514-0125, Japan; (M.N.); (K.S.); (P.B.T.)
- Correspondence: (J.X.A.); (K.T.)
| |
Collapse
|
8
|
Lee JY, Baek SH, Ahn JG, Yoon SH, Kim MK, Kim SY, Kim KW, Sohn MH, Kang JM. Delayed Influenza Treatment in Children With False-Negative Rapid Antigen Test: A Retrospective Single-Center Study in Korea 2016-2019. J Korean Med Sci 2022; 37:e3. [PMID: 34981679 PMCID: PMC8723894 DOI: 10.3346/jkms.2022.37.e3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2021] [Accepted: 11/09/2021] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND We aimed to examine the delay in antiviral initiation in rapid antigen test (RAT) false-negative children with influenza virus infection and to explore the clinical outcomes. We additionally conducted a medical cost-benefit analysis. METHODS This single-center, retrospective study included children (aged < 10 years) with influenza-like illness (ILI), hospitalized after presenting to the emergency department during three influenza seasons (2016-2019). RAT-false-negativity was defined as RAT-negative and polymerase chain reaction-positive cases. The turnaround time to antiviral treatment (TAT) was from the time when RAT was prescribed to the time when the antiviral was administered. The medical cost analysis by scenarios was also performed. RESULTS A total of 1,430 patients were included, 7.5% were RAT-positive (n = 107) and 2.4% were RAT-false-negative (n = 20). The median TAT of RAT-false-negative patients was 52.8 hours, significantly longer than that of 4 hours in RAT-positive patients (19.2-100.1, P < 0.001). In the multivariable analysis, TAT of ≥ 24 hours was associated with a risk of severe influenza infection and the need for mechanical ventilation (odds ratio [OR], 6.8, P = 0.009 and OR, 16.2, P = 0.033, respectively). The medical cost varied from $11.7-187.3/ILI patient. CONCLUSION Antiviral initiation was delayed in RAT-false-negative patients. Our findings support the guideline that children with influenza, suspected of having severe or progressive infection, should be treated immediately.
Collapse
Affiliation(s)
- Ji Young Lee
- Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Seung Hwan Baek
- Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Jong Gyun Ahn
- Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea
- Institute for Immunology and Immunological Disease, Yonsei University College of Medicine, Seoul, Korea
| | - Seo Hee Yoon
- Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Moon Kyu Kim
- Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Soo Yeon Kim
- Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Kyung Won Kim
- Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Myung Hyun Sohn
- Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Ji-Man Kang
- Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea
- Institute for Immunology and Immunological Disease, Yonsei University College of Medicine, Seoul, Korea.
| |
Collapse
|
9
|
Wang H, Hogan CA, Verghese M, Solis D, Sibai M, Huang C, Röltgen K, Stevens BA, Yamamoto F, Sahoo MK, Zehnder J, Boyd SD, Pinsky BA. SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19. Clin Chem 2021; 68:204-213. [PMID: 34605900 PMCID: PMC8522398 DOI: 10.1093/clinchem/hvab216] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Accepted: 09/10/2021] [Indexed: 11/30/2022]
Abstract
BACKGROUND Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid antigen in blood has been described, but the diagnostic and prognostic role of antigenemia is not well understood. This study aimed to determine the frequency, duration, and concentration of nucleocapsid antigen in plasma and its association with coronavirus disease 2019 (COVID-19) severity. METHODS We utilized an ultrasensitive electrochemiluminescence immunoassay targeting SARS-CoV-2 nucleocapsid antigen to evaluate 777 plasma samples from 104 individuals with COVID-19. We compared plasma antigen to respiratory nucleic acid amplification testing (NAAT) in 74 individuals with COVID-19 from samples collected ±1 day of diagnostic respiratory NAAT and in 52 SARS-CoV-2-negative individuals. We used Kruskal-Wallis tests, multivariable logistic regression, and mixed-effects modeling to evaluate whether plasma antigen concentration was associated with disease severity. RESULTS Plasma antigen had 91.9% (95% CI 83.2%-97.0%) clinical sensitivity and 94.2% (84.1%-98.8%) clinical specificity. Antigen-negative plasma samples belonged to patients with later respiratory cycle thresholds (Ct) when compared with antigen-positive plasma samples. Median plasma antigen concentration (log10 fg/mL) was 5.4 (interquartile range 3.9-6.0) in outpatients, 6.0 (5.4-6.5) in inpatients, and 6.6 (6.1-7.2) in intensive care unit (ICU) patients. In models adjusted for age, sex, diabetes, and hypertension, plasma antigen concentration at diagnosis was associated with ICU admission [odds ratio 2.8 (95% CI 1.2-6.2), P=.01] but not with non-ICU hospitalization. Rate of antigen decrease was not associated with disease severity. CONCLUSIONS SARS-CoV-2 plasma nucleocapsid antigen exhibited comparable diagnostic performance to upper respiratory NAAT, especially among those with late respiratory Ct. In addition to currently available tools, antigenemia may facilitate patient triage to optimize intensive care utilization.
Collapse
Affiliation(s)
- Hannah Wang
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - Catherine A Hogan
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - Michelle Verghese
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - Daniel Solis
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - Mamdouh Sibai
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - ChunHong Huang
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - Katharina Röltgen
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - Bryan A Stevens
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - Fumiko Yamamoto
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - Malaya K Sahoo
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - James Zehnder
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - Scott D Boyd
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - Benjamin A Pinsky
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
- Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
| |
Collapse
|
10
|
Rubin EJ, Baden LR, Morrissey S. Audio Interview: How Much Protection Does Prior SARS-CoV-2 Infection Provide? N Engl J Med 2021; 385:e100. [PMID: 34910868 DOI: 10.1056/nejme2119539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
11
|
Files JK, Sarkar S, Fram TR, Boppana S, Sterrett S, Qin K, Bansal A, Long DM, Sabbaj S, Kobie JJ, Goepfert PA, Erdmann N. Duration of post-COVID-19 symptoms is associated with sustained SARS-CoV-2-specific immune responses. JCI Insight 2021; 6:151544. [PMID: 34143754 PMCID: PMC8410022 DOI: 10.1172/jci.insight.151544] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Accepted: 06/17/2021] [Indexed: 11/17/2022] Open
Abstract
A subset of COVID-19 patients exhibit post-acute sequelae of COVID-19 (PASC), but little is known about the immune signatures associated with these syndromes. We investigated longitudinal peripheral blood samples in 50 individuals with previously confirmed SARS-CoV-2 infection, including 20 who experienced prolonged duration of COVID-19 symptoms (lasting more than 30 days; median = 74 days) compared with 30 who had symptom resolution within 20 days. Individuals with prolonged symptom duration maintained antigen-specific T cell response magnitudes to SARS-CoV-2 spike protein in CD4+ and circulating T follicular helper cell populations during late convalescence, while those without persistent symptoms demonstrated an expected decline. The prolonged group also displayed increased IgG avidity to SARS-CoV-2 spike protein. Significant correlations between symptom duration and both SARS-CoV-2-specific T cells and antibodies were observed. Activation and exhaustion markers were evaluated in multiple immune cell types, revealing few phenotypic differences between prolonged and recovered groups, suggesting that prolonged symptom duration is not due to persistent systemic inflammation. These findings demonstrate that SARS-CoV-2-specific immune responses are maintained in patients suffering from prolonged post-COVID-19 symptom duration in contrast to those with resolved symptoms and may suggest the persistence of viral antigens as an underlying etiology.
Collapse
Affiliation(s)
- Jacob K. Files
- Division of Infectious Diseases, Department of Medicine, School of Medicine
| | - Sanghita Sarkar
- Division of Infectious Diseases, Department of Medicine, School of Medicine
| | - Tim R. Fram
- Division of Infectious Diseases, Department of Medicine, School of Medicine
| | - Sushma Boppana
- Division of Infectious Diseases, Department of Medicine, School of Medicine
| | - Sarah Sterrett
- Division of Infectious Diseases, Department of Medicine, School of Medicine
| | - Kai Qin
- Division of Infectious Diseases, Department of Medicine, School of Medicine
| | - Anju Bansal
- Division of Infectious Diseases, Department of Medicine, School of Medicine
| | - Dustin M. Long
- Department of Biostatistics, School of Public Health, and
| | - Steffanie Sabbaj
- Division of Infectious Diseases, Department of Medicine, School of Medicine
- Department of Microbiology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - James J. Kobie
- Division of Infectious Diseases, Department of Medicine, School of Medicine
| | - Paul A. Goepfert
- Division of Infectious Diseases, Department of Medicine, School of Medicine
- Department of Microbiology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Nathan Erdmann
- Division of Infectious Diseases, Department of Medicine, School of Medicine
| |
Collapse
|
12
|
Belogiannis K, Florou VA, Fragkou PC, Ferous S, Chatzis L, Polyzou A, Lagopati N, Vassilakos D, Kittas C, Tzioufas AG, Tsiodras S, Sourvinos G, Gorgoulis VG. SARS-CoV-2 Antigenemia as a Confounding Factor in Immunodiagnostic Assays: A Case Study. Viruses 2021; 13:v13061143. [PMID: 34198719 PMCID: PMC8232125 DOI: 10.3390/v13061143] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Revised: 06/08/2021] [Accepted: 06/09/2021] [Indexed: 12/11/2022] Open
Abstract
Humoral immunity has emerged as a vital immune component against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nevertheless, a subset of recovered Coronavirus Disease-2019 (COVID-19) paucisymptomatic/asymptomatic individuals do not generate an antibody response, constituting a paradox. We assumed that immunodiagnostic assays may operate under a competitive format within the context of antigenemia, potentially explaining this phenomenon. We present a case where persistent antigenemia/viremia was documented for at least 73 days post-symptom onset using ‘in-house’ methodology, and as it progressively declined, seroconversion took place late, around day 55, supporting our hypothesis. Thus, prolonged SARS-CoV-2 antigenemia/viremia could mask humoral responses, rendering, in certain cases, the phenomenon of ‘non-responders’ a misnomer.
Collapse
Affiliation(s)
- Konstantinos Belogiannis
- Molecular Carcinogenesis Group, Department of Histology and Embryology, Medical School, National and Kapodistrian University of Athens, GR-11527 Athens, Greece; (K.B.); (V.A.F.); (A.P.); (N.L.); (D.V.); (C.K.)
| | - Venetia A. Florou
- Molecular Carcinogenesis Group, Department of Histology and Embryology, Medical School, National and Kapodistrian University of Athens, GR-11527 Athens, Greece; (K.B.); (V.A.F.); (A.P.); (N.L.); (D.V.); (C.K.)
| | - Paraskevi C. Fragkou
- 4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, GR-12462 Athens, Greece; (P.C.F.); (S.T.)
| | - Stefanos Ferous
- 2nd Medical Department, General Hospital of Athens G. Gennimatas, GR-11527 Athens, Greece;
| | - Loukas Chatzis
- Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, GR-11527 Athens, Greece; (L.C.); (A.G.T.)
| | - Aikaterini Polyzou
- Molecular Carcinogenesis Group, Department of Histology and Embryology, Medical School, National and Kapodistrian University of Athens, GR-11527 Athens, Greece; (K.B.); (V.A.F.); (A.P.); (N.L.); (D.V.); (C.K.)
| | - Nefeli Lagopati
- Molecular Carcinogenesis Group, Department of Histology and Embryology, Medical School, National and Kapodistrian University of Athens, GR-11527 Athens, Greece; (K.B.); (V.A.F.); (A.P.); (N.L.); (D.V.); (C.K.)
- Manchester Academic Health Sciences Centre, Division of Cancer Sciences, University of Manchester, Manchester M13 9NQ, UK
| | - Demetrios Vassilakos
- Molecular Carcinogenesis Group, Department of Histology and Embryology, Medical School, National and Kapodistrian University of Athens, GR-11527 Athens, Greece; (K.B.); (V.A.F.); (A.P.); (N.L.); (D.V.); (C.K.)
| | - Christos Kittas
- Molecular Carcinogenesis Group, Department of Histology and Embryology, Medical School, National and Kapodistrian University of Athens, GR-11527 Athens, Greece; (K.B.); (V.A.F.); (A.P.); (N.L.); (D.V.); (C.K.)
| | - Athanasios G. Tzioufas
- Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, GR-11527 Athens, Greece; (L.C.); (A.G.T.)
| | - Sotirios Tsiodras
- 4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, GR-12462 Athens, Greece; (P.C.F.); (S.T.)
| | - George Sourvinos
- Laboratory of Clinical Virology, Medical School, University of Crete, Crete, GR-71003 Heraklion, Greece
- Correspondence: (G.S.); (V.G.G.)
| | - Vassilis G. Gorgoulis
- Molecular Carcinogenesis Group, Department of Histology and Embryology, Medical School, National and Kapodistrian University of Athens, GR-11527 Athens, Greece; (K.B.); (V.A.F.); (A.P.); (N.L.); (D.V.); (C.K.)
- Manchester Academic Health Sciences Centre, Division of Cancer Sciences, University of Manchester, Manchester M13 9NQ, UK
- Biomedical Research Foundation, Academy of Athens, GR-11527 Athens, Greece
- Center for New Biotechnologies and Precision Medicine, Medical School, National and Kapodistrian University of Athens, GR-11527 Athens, Greece
- Correspondence: (G.S.); (V.G.G.)
| |
Collapse
|
13
|
Ngim CF, Husain SMT, Hassan SS, Dhanoa A, Ahmad SAA, Mariapun J, Wan Ismail WF, Botross Henien NP, Jahan NK, Pong LY, Elshahawi H, Hontz RD, Warkentein T, Yunos NM. Rapid testing requires clinical evaluation for accurate diagnosis of dengue disease: A passive surveillance study in Southern Malaysia. PLoS Negl Trop Dis 2021; 15:e0009445. [PMID: 34014983 PMCID: PMC8171949 DOI: 10.1371/journal.pntd.0009445] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2020] [Revised: 06/02/2021] [Accepted: 05/04/2021] [Indexed: 11/18/2022] Open
Abstract
Background Dengue fever is the most common mosquito-borne infection worldwide where an expanding surveillance and characterization of this infection are needed to better inform the healthcare system. In this surveillance-based study, we explored the prevalence and distinguishing features of dengue fever amongst febrile patients in a large community-based health facility in southern peninsular Malaysia. Methods Over six months in 2018, we recruited 368 adults who met the WHO 2009 criteria for probable dengue infection. They underwent the following blood tests: full blood count, dengue virus (DENV) rapid diagnostic test (RDT), ELISA (dengue IgM and IgG), nested RT-PCR for dengue, multiplex qRT-PCR for Zika, Chikungunya and dengue as well as PCR tests for Leptopspira spp., Japanese encephalitis and West Nile virus. Results Laboratory-confirmed dengue infections (defined by positive tests in NS1, IgM, high-titre IgG or nested RT-PCR) were found in 167 (45.4%) patients. Of these 167 dengue patients, only 104 (62.3%) were positive on rapid diagnostic testing. Dengue infection was significantly associated with the following features: family or neighbours with dengue in the past week (AOR: 3.59, 95% CI:2.14–6.00, p<0.001), cutaneous rash (AOR: 3.58, 95% CI:1.77–7.23, p<0.001), increased temperature (AOR: 1.33, 95% CI:1.04–1.70, p = 0.021), leucopenia (white cell count < 4,000/μL) (AOR: 3.44, 95% CI:1.72–6.89, p<0.001) and thrombocytopenia (platelet count <150,000/μL)(AOR: 4.63, 95% CI:2.33–9.21, p<0.001). Dengue infection was negatively associated with runny nose (AOR: 0.47, 95% CI:0.29–0.78, p = 0.003) and arthralgia (AOR: 0.42, 95% CI:0.24–0.75, p = 0.004). Serotyping by nested RT-PCR revealed mostly mono-infections with DENV-2 (n = 64), DENV-1 (n = 32) and DENV-3 (n = 17); 14 co-infections occurred with DENV-1/DENV-2 (n = 13) and DENV-1/DENV-4 (n = 1). Besides dengue, none of the pathogens above were found in patients’ serum. Conclusions Acute undifferentiated febrile infections are a diagnostic challenge for community-based clinicians. Rapid diagnostic tests are increasingly used to diagnose dengue infection but negative tests should be interpreted with caution as they fail to detect a considerable proportion of dengue infection. Certain clinical features and haematological parameters are important in the clinical diagnosis of dengue infection. With the rise in dengue infection worldwide, dengue fever remains an important diagnosis among patients presenting with fever in the community. We conducted a passive surveillance study in a large community clinic in southern Malaysia. Adults with fever who met the WHO 2009 criteria for probable dengue infection underwent blood tests that were able to detect dengue fever accurately, including rapid diagnostics tests, serology, and molecular tests. Nearly half (45.4%) of the patients were confirmed to suffer from dengue infection in which the widely-used rapid tests were negative in a considerable proportion of dengue-infected patients. This underlines the importance of recognizing clinical and laboratory features suggestive of dengue fever. We found that a history of family or neighbours with dengue infection in the past week, skin rash, a higher temperature, leucopenia (white cell count < 4,000/μL) and thrombocytopenia (platelet count <150,000/μL) were significantly associated with dengue fever whereas runny nose and arthralgia were features that suggest non-dengue conditions. These features in addition to rapid diagnostic kits are useful to guide community based health care workers in the diagnosis of patients presenting with undifferentiated fever.
Collapse
Affiliation(s)
- Chin Fang Ngim
- Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Malaysia
- * E-mail:
| | | | - Sharifah Syed Hassan
- Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Malaysia
| | - Amreeta Dhanoa
- Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Malaysia
| | | | - Jeevitha Mariapun
- Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Malaysia
| | | | | | - Nowrozy Kamar Jahan
- Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Malaysia
| | - Lian Yih Pong
- Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Malaysia
| | - Hesham Elshahawi
- Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Malaysia
| | | | | | - Nor’azim Mohd Yunos
- Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Malaysia
- Faculty of Medicine, University of Malaya, Malaysia
| |
Collapse
|
14
|
Abbasi J. A Next-Generation Rapid, Accurate SARS-CoV-2 Antibody Test. JAMA 2021; 325:1825. [PMID: 33974035 DOI: 10.1001/jama.2021.6333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
15
|
Abstract
COVID-19, caused by the SARS-CoV-2 virus, has developed into a global health crisis, causing over 2 million deaths and changing people's daily life the world over. Current main-stream diagnostic methods in the laboratory include nucleic acid PCR tests and direct viral antigen tests for detecting active infections, and indirect human antibody tests specific to SARS-CoV-2 to detect prior exposure. In this Perspective, we briefly describe the PCR and antigen tests and then focus mainly on existing antibody tests and their limitations including inaccuracies and possible causes of unreliability. False negatives in antibody immunoassays can arise from assay formats, selection of viral antigens and antibody types, diagnostic testing windows, individual variance, and fluctuation in antibody levels. Reasons for false positives in antibody immunoassays mainly involve antibody cross-reactivity from other viruses, as well as autoimmune disease. The spectrum bias has an effect on both the false negatives and false positives. For assay developers, not only improvement of assay formats but also selection of viral antigens and isotopes of human antibodies need to be carefully considered to improve sensitivity and specificity. For clinicians, the factors influencing the accuracy of assays must be kept in mind to test patients using currently imperfect but available tests with smart tactics and realistic interpretation of the test results.
Collapse
Affiliation(s)
- Guoqiang Liu
- Medical College, Jiaxing
University, 118 Jiahang Road, Jiaxing, Zhejiang Province,
China
- Department of Chemistry, University of
Connecticut, 55 North Eagleville Road, Storrs, Connecticut 06269,
United States
| | - James F. Rusling
- Department of Chemistry, University of
Connecticut, 55 North Eagleville Road, Storrs, Connecticut 06269,
United States
- Department of Surgery and Neag Cancer Center,
UConn Health, Farmington, Connecticut 06232, United
States
- Institute of Materials Science,
University of Connecticut, 97 North Eagleville Road, Storrs,
Connecticut 0626, United States
- School of Chemistry, National University
of Ireland Galway, University Road, Galway,
Ireland
| |
Collapse
|
16
|
Ciccullo A, Tosato M, Borghetti A, Moschese D, Fantoni M, Di Giambenedetto S, Landi F. Determinants of SARS-COV-2 seroconversion in a cohort of recovered patients. Infez Med 2021; 29:163-164. [PMID: 33664188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Not available.
Collapse
Affiliation(s)
- Arturo Ciccullo
- UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | - Matteo Tosato
- Geriatrics Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | - Alberto Borghetti
- UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | - Davide Moschese
- UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | - Massimo Fantoni
- UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | - Simona Di Giambenedetto
- UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | - Francesco Landi
- Geriatrics Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| |
Collapse
|
17
|
|
18
|
Candel FJ, Barreiro P, San Román J, Abanades JC, Barba R, Barberán J, Bibiano C, Canora J, Cantón R, Calvo C, Carretero M, Cava F, Delgado R, García-Rodríguez J, González Del Castillo J, González de Villaumbrosia C, Hernández M, Losa JE, Martínez-Peromingo FJ, Molero JM, Muñoz P, Onecha E, Onoda M, Rodríguez J, Sánchez-Celaya M, Serra JA, Zapatero A. Recommendations for use of antigenic tests in the diagnosis of acute SARS-CoV-2 infection in the second pandemic wave: attitude in different clinical settings. Rev Esp Quimioter 2020; 33:466-484. [PMID: 33070578 PMCID: PMC7712344 DOI: 10.37201/req/120.2020] [Citation(s) in RCA: 38] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Accepted: 10/14/2020] [Indexed: 01/10/2023]
Abstract
The high transmissibility of SARS-CoV-2 before and shortly after the onset of symptoms suggests that only diagnosing and isolating symptomatic patients may not be sufficient to interrupt the spread of infection; therefore, public health measures such as personal distancing are also necessary. Additionally, it will be important to detect the newly infected individuals who remain asymptomatic, which may account for 50% or more of the cases. Molecular techniques are the "gold standard" for the diagnosis of SARS-CoV-2 infection. However, the massive use of these techniques has generated some problems. On the one hand, the scarcity of resources (analyzers, fungibles and reagents), and on the other the delay in the notification of results. These two facts translate into a lag in the application of isolation measures among cases and contacts, which favors the spread of the infection. Antigen detection tests are also direct diagnostic methods, with the advantage of obtaining the result in a few minutes and at the very "pointof-care". Furthermore, the simplicity and low cost of these tests allow them to be repeated on successive days in certain clinical settings. The sensitivity of antigen tests is generally lower than that of nucleic acid tests, although their specificity is comparable. Antigenic tests have been shown to be more valid in the days around the onset of symptoms, when the viral load in the nasopharynx is higher. Having a rapid and real-time viral detection assay such as the antigen test has been shown to be more useful to control the spread of the infection than more sensitive tests, but with greater cost and response time, such as in case of molecular tests. The main health institutions such as the WHO, the CDC and the Ministry of Health of the Government of Spain propose the use of antigenic tests in a wide variety of strategies to respond to the pandemic. This document aims to support physicians involved in the care of patients with suspected SC2 infection, in the context of a growing incidence in Spain since September 2020, which already represents the second pandemic wave of COVID-19.
Collapse
Affiliation(s)
- F J Candel
- Dr. Francisco Javier Candel. Enfermedades Infecciosas y Microbiología Clínica. Hospital Clínico San Carlos. Institutos IdISSC e IML. Profesor Asociado. Facultad de Medicina. UCM. Madrid. Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
van Tol S, Mögling R, Li W, Godeke GJ, Swart A, Bergmans B, Brandenburg A, Kremer K, Murk JL, van Beek J, Wintermans B, Reimerink J, Bosch BJ, Reusken C. Accurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach. Emerg Microbes Infect 2020; 9:1965-1973. [PMID: 32819220 PMCID: PMC8284965 DOI: 10.1080/22221751.2020.1813636] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Accepted: 08/19/2020] [Indexed: 01/10/2023]
Abstract
Serology is a crucial part of the public health response to the ongoing SARS-CoV-2 pandemic. Here, we describe the development, validation and clinical evaluation of a protein micro-array as a quantitative multiplex immunoassay that can identify S and N-directed SARS-CoV-2 IgG antibodies with high specificity and sensitivity and distinguish them from all currently circulating human coronaviruses. The method specificity was 100% for SARS-CoV-2 S1 and 96% for N antigen based on extensive syndromic (n=230 cases) and population panel (n=94) testing that also confirmed the high prevalence of seasonal human coronaviruses. To assess its potential role for both SARS-CoV-2 patient diagnostics and population studies, we evaluated a large heterogeneous COVID-19 cohort (n=330) and found an overall sensitivity of 89% (≥ 21 days post onset symptoms (dps)), ranging from 86% to 96% depending on severity of disease. For a subset of these patients longitudinal samples were provided up to 56 dps. Mild cases showed absent or delayed, and lower SARS-CoV-2 antibody responses. Overall, we present the development and extensive clinical validation of a multiplex coronavirus serological assay for syndromic testing, to answer research questions regarding to antibody responses, to support SARS-CoV-2 diagnostics and to evaluate epidemiological developments efficiently and with high-throughput.
Collapse
Affiliation(s)
- Sophie van Tol
- Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Ramona Mögling
- Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Wentao Li
- Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - Gert-Jan Godeke
- Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Arno Swart
- Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Barbara Bergmans
- Microvida, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands
| | - Afke Brandenburg
- Izore Centre for Infectious Diseases Friesland, Leeuwarden, The Netherlands
| | - Kristin Kremer
- Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Jean-Luc Murk
- Microvida, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands
| | - Josine van Beek
- Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Bas Wintermans
- Department of Medical Microbiology and Immunology, Admiral De Ruyter Hospital, Goes, The Netherlands
- Department of Medical Microbiology, Bravis Hospital, Roosendaal, The Netherlands
| | - Johan Reimerink
- Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Berend-Jan Bosch
- Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - Chantal Reusken
- Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| |
Collapse
|
20
|
Affiliation(s)
- Vicente Soriano
- UNIR Health Sciences School and Medical Center, Madrid, Spain
| | | | | |
Collapse
|
21
|
Kimitsuki K, Saito N, Yamada K, Park CH, Inoue S, Suzuki M, Saito-Obata M, Kamiya Y, Manalo DL, Demetria CS, Mananggit MR, Quiambao BP, Nishizono A. Evaluation of the diagnostic accuracy of lateral flow devices as a tool to diagnose rabies in post-mortem animals. PLoS Negl Trop Dis 2020; 14:e0008844. [PMID: 33151941 PMCID: PMC7671516 DOI: 10.1371/journal.pntd.0008844] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Revised: 11/17/2020] [Accepted: 09/28/2020] [Indexed: 11/19/2022] Open
Abstract
Implementation of lateral flow devices (LFDs) for rabies antigen detection is expected to improve surveillance through the efficient detection of rabid animals in resource-limited settings; however, the use of LFDs for diagnosis remains controversial because some commercially available kits show low sensitivity. Therefore, we compared the diagnostic efficacy of three LFDs (ADTEC, Bionote, and Elabscience kits) paralleled with the direct fluorescent antibody test (dFAT) using fresh samples and investigated the diagnostic accuracies. To do so, we evaluated rabies-suspected samples submitted to the Regional Animal Disease Diagnostic Laboratory III, Philippines. Furthermore, we conducted real-time RT-PCR and sequencing to measure the accuracy of field laboratory diagnosis. The total number of animals submitted during this study period was 184 cases, including negative control samples. Of these, 53.9% (84 cases) were positive in the dFAT. Dogs were the most common rabies-suspected animal (n = 135). The sensitivities of the ADTEC and Bionote kits were 0.88 (74 cases) and 0.95 (80 cases), respectively. The specificity of both kits was 1.00 (100 cases). Furthermore, the sensitivity and specificity of the ADTEC kit after directly homogenizing the samples in assay buffer without dilution in phosphate-buffered saline (ADTEC kit DM) were 0.94 (79 cases) and 1.00 (100 cases), respectively. By contrast, there were no positive results using the Elabscience kit among all dFAT-positive samples. The sensitivity and specificity of LFDs make these tests highly feasible if properly used. Therefore, LFD tests can be used to strengthen the surveillance of rabies-infected animals in endemic and resource-limited settings.
Collapse
Affiliation(s)
- Kazunori Kimitsuki
- Department of Microbiology, Faculty of Medicine, Oita University, Yufu, Oita, Japan
| | - Nobuo Saito
- Department of Microbiology, Faculty of Medicine, Oita University, Yufu, Oita, Japan
| | - Kentaro Yamada
- Laboratory of Veterinary Public Health, Department of Veterinary Medical Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Miyazaki, Japan
| | - Chun-Ho Park
- Department of Veterinary Pathology, School of Veterinary Medicine, Kitasato University, Towada, Aomori, Japan
| | - Satoshi Inoue
- National Institute of Infectious Disease, Tokyo, Japan
| | - Motoi Suzuki
- National Institute of Infectious Disease, Tokyo, Japan
| | | | - Yasuhiko Kamiya
- School of Tropical Medicine & Global Health, Nagasaki University, Nagasaki, Nagasaki, Japan
| | - Daria L. Manalo
- Research Institute for Tropical Medicine, Muntinlupa City, Metro Manila, Philippines
| | - Catalino S. Demetria
- Research Institute for Tropical Medicine, Muntinlupa City, Metro Manila, Philippines
| | - Milagros R. Mananggit
- Regional Animal Disease Diagnostic Laboratory, Department of Agriculture Field Office III, San Fernando, Pampanga, Philippines
| | - Beatriz P. Quiambao
- Research Institute for Tropical Medicine, Muntinlupa City, Metro Manila, Philippines
| | - Akira Nishizono
- Department of Microbiology, Faculty of Medicine, Oita University, Yufu, Oita, Japan
- * E-mail:
| |
Collapse
|
22
|
Abstract
In the past four months SARS-CoV-2 has reached most countries in the world. Public health strategies based on widespread testing and proper isolation of positive cases have shown to be helpful to reduce local transmission of SARS-CoV-2. Confirmatory tests, that identify viral RNA, and screening serological tests that identify viral antigens or host antibodies against viral proteins are part of the tools that nations can use to fight infectious disease epidemics. Understanding how each test works can provide insights about their test characteristics and how they can be used for different clinical and public health goals. Testing is a key strategy to reduce viral transmission, not only for this epidemic, but also for others to come.
Collapse
Affiliation(s)
- Julián Santaella-Tenorio
- Universidad del Valle; Escuela de Salud Pública, Facultad de Salud. Cali, Colombia
- Pontificia Universidad Javeriana, Maestría en Epidemiología Clínica, Cali, Colombia
| |
Collapse
|
23
|
Peravali R, Acharya S, Raza SH, Pattanaik D, Randall MB. Dermatomyositis Developed After Exposure to Epstein-Barr Virus Infection and Antibiotics Use. Am J Med Sci 2020; 360:402-405. [PMID: 32591093 DOI: 10.1016/j.amjms.2020.05.011] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2020] [Revised: 03/30/2020] [Accepted: 05/07/2020] [Indexed: 11/19/2022]
Abstract
Dermatomyositis is an inflammatory disorder involving muscle and skin. Similar to many other autoimmune diseases, environmental factors appear to trigger the onset of disease in some cases. Many drugs have been reported to be associated with dermatomyositis, and rarely infections have been described as potential triggering agents. Here we are describing a case of dermatomyositis that developed after doxycycline and levofloxacin use, who also had recent Epstein-Barr virus infection. Dermatomyositis associated with doxycycline or levofloxacin use has not yet been described in the literature, while reports of dermatomyositis after Epstein-Barr virus infection have been rare and limited to juvenile dermatomyositis or in association with cancer. It is important for clinicians to be aware of this rare association so that the diagnosis and treatment can be exercised promptly.
Collapse
Affiliation(s)
- Rahul Peravali
- University of Tennessee Medical School, Memphis, Tennessee
| | - Saurav Acharya
- Division of Rheumatology, University of Tennessee Health Science Center, Memphis, Tennessee.
| | - Syed Hasan Raza
- Division of Rheumatology, University of Tennessee Health Science Center, Memphis, Tennessee
| | - Debendra Pattanaik
- Division of Rheumatology, University of Tennessee Health Science Center, Memphis, Tennessee
| | - Milton Barry Randall
- Department of Dermatology, University of Tennessee Health Science Center, Memphis, Tennessee
| |
Collapse
|
24
|
Hallmann-Szelińska E, Szymański K, Łuniewska K, Kondratiuk K, Brydak LB. Hemagglutination inhibition antibody titers as a correlate of protection against influenza disease in the 2018/2019 epidemic season in Poland. Acta Biochim Pol 2020; 67:93-98. [PMID: 32182410 DOI: 10.18388/abp.2020_5088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2019] [Accepted: 01/28/2020] [Indexed: 11/10/2022]
Abstract
The aim of this study was to determine the level of antibodies against hemagglutinin of influenza viruses in the sera of people in the seven age groups in the epidemic season 2018/2019 in Poland. The level of anti-hemagglutinin antibodies was determined by hemagglutination inhibition test (HAI). 1050 clinical samples from all over the country were tested. The level of antibodies against influenza viruses was highest in the 10-14 age group for A/Singapore/INFIMH-16-0019/2016 (H3N2) and B/Phuket/3073/2013 Yamagata lineage antigens. These results confirm the circulation of four antigenically different influenza virus strains, two subtypes of influenza A virus - A/Michigan/45/2015 (H1N1)pdm09 and A/Singapore/INFIMH-16-0019/2016 (H3N2) and two lineages of influenza B virus - B/Colorado/06/2017 - Victoria lineage and B/Phuket/3073/2013 Yamagata lineage.
Collapse
Affiliation(s)
- Ewelina Hallmann-Szelińska
- Department of Influenza Research - National Influenza Center, National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland
| | - Karol Szymański
- Department of Influenza Research - National Influenza Center, National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland
| | - Katarzyna Łuniewska
- Department of Influenza Research - National Influenza Center, National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland
| | - Katarzyna Kondratiuk
- Department of Influenza Research - National Influenza Center, National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland
| | - Lidia Bernadeta Brydak
- Department of Influenza Research - National Influenza Center, National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland
| |
Collapse
|
25
|
Masika MM, Korhonen EM, Smura T, Uusitalo R, Vapalahti K, Mwaengo D, Jääskeläinen AJ, Anzala O, Vapalahti O, Huhtamo E. Detection of dengue virus type 2 of Indian origin in acute febrile patients in rural Kenya. PLoS Negl Trop Dis 2020; 14:e0008099. [PMID: 32126086 PMCID: PMC7069648 DOI: 10.1371/journal.pntd.0008099] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2019] [Revised: 03/13/2020] [Accepted: 01/29/2020] [Indexed: 01/25/2023] Open
Abstract
Dengue virus (DENV) has caused recent outbreaks in coastal cities of Kenya, but the epidemiological situation in other areas of Kenya is largely unknown. We investigated the role of DENV infection as a cause of acute febrile disease in non-epidemic settings in rural and urban study areas in Kenya. Altogether, 560 patients were sampled in 2016–2017 in rural Taita–Taveta County (n = 327) and urban slums of Kibera, Nairobi (n = 233). The samples were studied for DENV IgM, IgG, NS1 antigen and flaviviral RNA. IgG seroprevalence was found to be higher in Taita–Taveta (14%) than in Nairobi (3%). Five Taita–Taveta patients were positive for flaviviral RNA, all identified as DENV-2, cosmopolitan genotype. Local transmission in Taita–Taveta was suspected in a patient without travel history. The sequence analysis suggested that DENV-2 strains circulating in coastal and southern Kenya likely arose from a single introduction from India. The molecular clock analyses dated the most recent ancestor to the Kenyan strains a year before the large 2013 outbreak in Mombasa. After this, the virus has been detected in Kilifi in 2014, from our patients in Taita–Taveta in 2016, and in an outbreak in Malindi in 2017. The results highlight that silent transmission occurs between epidemics and also affects rural areas. More information is needed to understand the local epidemiological characteristics and future risks of dengue in Kenya. Dengue virus (DENV) is an emerging mosquito-borne global health threat in the tropics and subtropics. The majority of the world’s population live in areas at risk of dengue that can cause a wide variety of symptoms from febrile illness to haemorrhagic fever. Information of DENV in Africa is limited and fragmented. In Kenya, dengue is a recognized disease in coastal cities that have experienced recent outbreaks. We investigated the role of DENV infection as a cause of acute febrile disease in non-epidemic settings in rural and urban study areas in Kenya. We found DENV-2 in five febrile patients from rural Taita–Taveta, where no dengue has been reported before. Genetic analysis of the virus suggests it to be most likely of Indian origin. This Indian origin DENV-2 was detected in the Mombasa outbreak in 2013, in Kilifi in 2014, in Taita–Taveta in 2016 (our study samples) and again in the Malindi outbreak in 2017. The results suggest that dengue is unrecognized in rural Kenya and more studies are needed for local risk assessment. Our findings of virus transmission between epidemics contribute to better understanding of the epidemiological situation and origins of DENV in Kenya.
Collapse
Affiliation(s)
- Moses Muia Masika
- Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya
- KAVI Institute of Clinical Research, University of Nairobi, Nairobi, Kenya
| | - Essi M. Korhonen
- Department of Virology, Medicum, University of Helsinki, Helsinki, Finland
- Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland
- * E-mail:
| | - Teemu Smura
- Department of Virology, Medicum, University of Helsinki, Helsinki, Finland
| | - Ruut Uusitalo
- Department of Virology, Medicum, University of Helsinki, Helsinki, Finland
- Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland
- Department of Geosciences and Geography, University of Helsinki, Helsinki, Finland
| | - Katariina Vapalahti
- Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland
| | - Dufton Mwaengo
- Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya
- Institute of Tropical and Infectious Diseases, University of Nairobi, Nairobi, Kenya
| | - Anne J. Jääskeläinen
- Department of Virology, Medicum, University of Helsinki, Helsinki, Finland
- Department of Virology and Immunology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
| | - Omu Anzala
- Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya
- KAVI Institute of Clinical Research, University of Nairobi, Nairobi, Kenya
| | - Olli Vapalahti
- Department of Virology, Medicum, University of Helsinki, Helsinki, Finland
- Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland
- Department of Virology and Immunology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
| | - Eili Huhtamo
- Department of Virology, Medicum, University of Helsinki, Helsinki, Finland
- Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland
| |
Collapse
|
26
|
Gauger PC, Vincent AL. Enzyme-Linked Immunosorbent Assay for Detection of Serum or Mucosal Isotype-Specific IgG and IgA Whole-Virus Antibody to Influenza A Virus in Swine. Methods Mol Biol 2020; 2123:311-320. [PMID: 32170697 DOI: 10.1007/978-1-0716-0346-8_22] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Enzyme-linked immunosorbent assays can be used to detect isotype-specific anti-influenza antibodies in biological samples to characterize the porcine immune response to influenza A virus (IAV). The isotype antibody assay is based on an indirect ELISA using whole influenza virus as antigen and commercial antibodies directed against porcine IgG and IgA. Samples such as serum, nasal wash, and bronchoalveolar lavage fluid allow for evaluation of systemic, upper, and lower respiratory tract mucosal antibody responses, respectively. The isotype ELISA assay is performed in a 96-well format using IAV test antigen and anti-swine IgG or IgA detection antibodies conjugated to an enzyme that catalyze a color change reaction. The optical density of the sample is measured using an automated plate reader. The assay is useful to characterize the IgG or IgA immune response to challenge or vaccination against specific IAV isolates in different compartments of the immune system.
Collapse
Affiliation(s)
- Phillip C Gauger
- Veterinary Diagnostic Laboratory, Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, USA.
| | - Amy L Vincent
- Virus and Prion Research Unit, National Animal Disease Center, USDA, Agricultural Research Service, Ames, IA, USA
| |
Collapse
|
27
|
Abstract
Introduction the COVID-19 pandemic, which results from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents important diagnostic challenges. Diagnostic strategies available to identify or rule out current infection, or to identify people in need of care escalation, or to test for past infection and immune response have become available, to reduce household and community transmission. We highlight a Cochrane review, published in September 2020, on the assessment of diagnostic accuracy of point-of-care antigen and molecular-based tests to determine current SARS-CoV-2 infection. Methods the authors of the Cochrane review searched multiple electronic databases for studies, which assessed SARS-CoV-2 infection with a diagnostic test. Eligible participants for the review included people with suspected current SARS-CoV-2 infection, known to have, or not to have COVID-19 infection, or where tests were used to screen for infection. Results the authors included 18 studies of point-of-care tests conducted in various parts of the world, with none from Africa. The review shows that there is considerable variability in sensitivity and specificity of the antigen tests. The review also shows that molecular tests had less variability in sensitivity and specificity. Conclusion the review suggests that the current evidence is not strong enough to determine the usefulness of point-of-care tests in all settings. However, the benefits are likely to be more noticeable in countries, like Africa where community transmission is high. An impact evaluation would be warranted when rapid point-of-care tests are implemented in African countries.
Collapse
Affiliation(s)
- Duduzile Ndwandwe
- Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa
- Corresponding author: Duduzile Ndwandwe, Cochrane South Africa, South African Medical Research Council, Francie van Zilj Drive, Parow Valley 7501, South Africa.
| | - Lindi Mathebula
- Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa
- Communicable Disease Control, Department of Health, Western Cape, South Africa
| | - Raoul Kamadjeu
- UNICEF Program Division, Public Health Emergencies Team, New York, USA
| | - Charles Shey Wiysonge
- Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa
- School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
- Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| |
Collapse
|
28
|
Gomez-Lucia E, Collado VM, Miró G, Martín S, Benítez L, Doménech A. Follow-Up of Viral Parameters in FeLV- or FIV-Naturally Infected Cats Treated Orally with Low Doses of Human Interferon Alpha. Viruses 2019; 11:v11090845. [PMID: 31514435 PMCID: PMC6783854 DOI: 10.3390/v11090845] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2019] [Revised: 08/23/2019] [Accepted: 09/08/2019] [Indexed: 01/05/2023] Open
Abstract
Specific treatments for the long-life infections by feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) are either toxic, expensive or not too effective. Interferon α (IFN-α) is an immunomodulatory molecule which has been shown in vitro to decrease the release of infective particles. The aim of this study was to follow the progress of the clinical score and viral parameters of FeLV- and FIV-naturally infected privately owned cats treated with recombinant human IFN-α (rHuIFN-α, Roferon-A). Twenty-seven FeLV-infected cats (FeLV+) and 31 FIV-infected cats (FIV+) were enrolled in the study. Owners were instructed to orally administer 1 mL/day of 60 IU rHuIFN-α/mL in alternating weeks for four months. Blood samples were taken at the beginning of the study (M0), mid-treatment (M2), end of treatment (M4), and 6-10 months later (M10). Clinical status at these time points improved notably with rHuIFN-α treatment, regardless of the initial severity of the disease, an effect which lasted throughout the study in most animals (15 of the 16 FeLV+ symptomatic cats; 20 of the 22 FIV+ symptomatic cats) improved markedly their clinical situation. In FeLV+ cats plasma antigenemia (p27CA), reverse transcriptase (RT) activity, and proviral load decreased at M2 and M4 but increased again at M10 ("rebound effect"). The level of antigenemia or RT activity was below the detection limits in FIV+ cats, and the effect on proviral load was less marked than in FeLV+ cats. Taken together, these results indicate that rHuIFN-α is a good candidate for treating FeLV+ cats, but the "rebound effect" seen when treatment was discontinued suggests that additional studies should be conducted to clarify its effect on progression of the infection in cats.
Collapse
Affiliation(s)
- Esperanza Gomez-Lucia
- Department of Animal Health, Veterinary Faculty, Complutense University of Madrid, 28040 Madrid, Spain.
| | - Victorio M Collado
- Department of Animal Health, Veterinary Faculty, Complutense University of Madrid, 28040 Madrid, Spain
| | - Guadalupe Miró
- Department of Animal Health, Veterinary Faculty, Complutense University of Madrid, 28040 Madrid, Spain
| | - Sonsoles Martín
- Department of Animal Medicine and Surgery, Veterinary Faculty, Complutense University of Madrid, 28040 Madrid, Spain
| | - Laura Benítez
- Department of Genetics, Physiology and Microbiology, Faculty of Biology, Complutense University of Madrid, José Antonio Novais, 12, 28040 Madrid, Spain
| | - Ana Doménech
- Department of Animal Health, Veterinary Faculty, Complutense University of Madrid, 28040 Madrid, Spain
| |
Collapse
|
29
|
Cui J, Yan W, Xie H, Xu S, Wang Q, Zhang W, Ni A. Cytomegalovirus antigenemia in patients with autoimmune and non-autoimmune diseases in Beijing: A 10-year single hospital experience. PLoS One 2019; 14:e0221793. [PMID: 31461496 PMCID: PMC6713388 DOI: 10.1371/journal.pone.0221793] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Accepted: 08/14/2019] [Indexed: 01/22/2023] Open
Abstract
Background Primary cytomegalovirus (CMV) infection is prevalent worldwide and usually results in latency in immunocompetent populations. Reactivation of latent CMV can cause life-threatening complications in immunocompromised hosts. Methods We used the CMV Brite assay to test CMV antigenemia (pp65) in whole blood samples from 22,192 patients with or without autoimmune diseases in Beijing during 2008–2018. Results The overall prevalence of CMV antigenemia was 19.5% (9.7%, males; 26.0%, females). The prevalence of CMV antigenemia was 35.1%, 58.6% and 11.4% in whole patients with autoimmune diseases, in patients with systemic lupus erythematosus (SLE) and in patients with non-SLE autoimmune diseases, respectively. All patients with non-autoimmune diseases, patients with HIV/AIDS or transplantation were found to have 5.0%, 27% or 14.8%, respectively. Patients≤20 years with SLE had a significantly higher prevalence of CMV antigenemia than did all SLE patients, on average. Patients>51 years with non-SLE autoimmune diseases had a significantly higher prevalence than did all patients with non-SLE autoimmune diseases, on average. The prevalence of CMV antigenemia in patients admitted to intensive-care units (ICUs) were 9.2%, which was significantly higher than that among all patients with non-autoimmune diseases. Patients with SLE had 23.8% of negative conversion of CMV antigenemia, significantly lower than the percentage of patients with non-SLE autoimmune (64.3%) and non-autoimmune (61.0%) diseases. The mean number of days to negative conversion of CMV antigenemia in patients with SLE was 35.3±35.8 days, which was significantly longer than that in patients with non-SLE autoimmune diseases (15.4±11.9 days) and non-autoimmune diseases (13.6±7.7 days). Conclusions CMV antigenemia is found more likely in women than in men, more prevalently in patients with SLE than those with HIV/AIDS or transplant recipients, more frequently in patients admitted to ICUs. Patients with SLE had prolonged CMV antigenemia. The role of CMV appears important in SLE.
Collapse
Affiliation(s)
- Jingtao Cui
- Department of Clinical Laboratories, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Wenjuan Yan
- Department of Clinical Laboratories, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Hongjie Xie
- Department of Clinical Laboratories, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Shaoxia Xu
- Department of Clinical Laboratories, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Qiaofeng Wang
- Department of Clinical Laboratories, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Weihong Zhang
- Department of Clinical Laboratories, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Anping Ni
- Department of Clinical Laboratories, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- * E-mail:
| |
Collapse
|
30
|
Mattiuzzo G, Bentley EM, Page M. The Role of Reference Materials in the Research and Development of Diagnostic Tools and Treatments for Haemorrhagic Fever Viruses. Viruses 2019; 11:v11090781. [PMID: 31450611 PMCID: PMC6783900 DOI: 10.3390/v11090781] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 08/15/2019] [Accepted: 08/21/2019] [Indexed: 11/16/2022] Open
Abstract
Following the Ebola outbreak in Western Africa in 2013–16, a global effort has taken place for preparedness for future outbreaks. As part of this response, the development of vaccines, treatments and diagnostic tools has been accelerated, especially towards pathogens listed as likely to cause an epidemic and for which there are no current treatments. Several of the priority pathogens identified by the World Health Organisation are haemorrhagic fever viruses. This review provides information on the role of reference materials as an enabling tool for the development and evaluation of assays, and ultimately vaccines and treatments. The types of standards available are described, along with how they can be applied for assay harmonisation through calibration as a relative potency to a common arbitrary unitage system (WHO International Unit). This assures that assay metrology is accurate and robust. We describe reference materials that have been or are being developed for haemorrhagic fever viruses and consider the issues surrounding their production, particularly that of biosafety where the viruses require specialised containment facilities. Finally, we advocate the use of reference materials at early stages, including research and development, as this helps produce reliable assays and can smooth the path to regulatory approval.
Collapse
MESH Headings
- Africa, Western/epidemiology
- Animals
- Antigens, Viral/blood
- Dengue Virus/immunology
- Dengue Virus/isolation & purification
- Dengue Virus/pathogenicity
- Diagnostic Techniques and Procedures
- Disease Outbreaks/prevention & control
- Ebolavirus/immunology
- Ebolavirus/isolation & purification
- Ebolavirus/pathogenicity
- Epidemics/prevention & control
- Hemorrhagic Fever Virus, Crimean-Congo/immunology
- Hemorrhagic Fever Virus, Crimean-Congo/isolation & purification
- Hemorrhagic Fever Virus, Crimean-Congo/pathogenicity
- Hemorrhagic Fever, Crimean/diagnosis
- Hemorrhagic Fever, Crimean/immunology
- Hemorrhagic Fever, Crimean/prevention & control
- Hemorrhagic Fever, Ebola/diagnosis
- Hemorrhagic Fever, Ebola/immunology
- Hemorrhagic Fever, Ebola/prevention & control
- Humans
- Information Services
- Lassa Fever/diagnosis
- Lassa Fever/immunology
- Lassa Fever/prevention & control
- Lassa virus/immunology
- Lassa virus/isolation & purification
- Lassa virus/pathogenicity
- Marburg Virus Disease/diagnosis
- Marburg Virus Disease/immunology
- Marburg Virus Disease/prevention & control
- Marburgvirus/immunology
- Marburgvirus/isolation & purification
- Marburgvirus/pathogenicity
- RNA Virus Infections/diagnosis
- RNA Virus Infections/immunology
- RNA Virus Infections/prevention & control
- RNA Viruses/immunology
- RNA Viruses/isolation & purification
- RNA Viruses/pathogenicity
- RNA, Viral/isolation & purification
- Rift Valley Fever/diagnosis
- Rift Valley Fever/immunology
- Rift Valley Fever/prevention & control
- Rift Valley fever virus/immunology
- Rift Valley fever virus/isolation & purification
- Rift Valley fever virus/pathogenicity
- Severe Dengue/diagnosis
- Severe Dengue/immunology
- Severe Dengue/prevention & control
- Vaccines/standards
- World Health Organization
Collapse
Affiliation(s)
- Giada Mattiuzzo
- Division of Virology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Hertfordshire EN6 3QG, UK.
| | - Emma M Bentley
- Division of Virology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Hertfordshire EN6 3QG, UK.
| | - Mark Page
- Division of Virology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Hertfordshire EN6 3QG, UK.
| |
Collapse
|
31
|
Mukaigawara M, Kinjo M, Olson AP, Raita Y, Murthy VK. Past is Prologue. J Hosp Med 2019; 14:501-505. [PMID: 31251159 DOI: 10.12788/jhm.3224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- Mitsuru Mukaigawara
- Department of Medicine, Okinawa Chubu Hospital, Uruma, Okinawa, Japan
- Department of Medicine, Okinawa Miyako Hospital, Miyakojima, Okinawa, Japan
| | - Mitsuyo Kinjo
- Department of Medicine, Okinawa Chubu Hospital, Uruma, Okinawa, Japan
| | - Andrew Pj Olson
- Departments of Medicine and Pediatrics, University of Minnesota, Minneapolis, Minnesota
| | - Yoshihiko Raita
- Department of Medicine, Okinawa Chubu Hospital, Uruma, Okinawa, Japan
- Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - Vivek K Murthy
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
| |
Collapse
|
32
|
Zang F, Su Z, Zhou L, Konduru K, Kaplan G, Chou SY. Ultrasensitive Ebola Virus Antigen Sensing via 3D Nanoantenna Arrays. Adv Mater 2019; 31:e1902331. [PMID: 31168856 DOI: 10.1002/adma.201902331] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Revised: 05/15/2019] [Indexed: 05/29/2023]
Abstract
Sensitive detection of pathogens is crucial for early disease diagnosis and quarantine, which is of tremendous need in controlling severe and fatal illness epidemics such as of Ebola virus (EBOV) disease. Serology assays can detect EBOV-specific antigens and antibodies cost-effectively without sophisticated equipment; however, they are less sensitive than reverse transcriptase polymerase chain reaction (RT-PCR) tests. Herein, a 3D plasmonic nanoantenna assay sensor is developed as an on-chip immunoassay platform for ultrasensitive detection of Ebola virus (EBOV) antigens. The EBOV sensor exhibits substantial fluorescence intensity enhancement in immunoassays compared to flat gold substrate. The nanoantenna-based biosensor successfully detects EBOV soluble glycoprotein (sGP) in human plasma down to 220 fg mL-1 , a significant 240 000-fold sensitivity improvement compared to the 53 ng mL-1 EBOV antigen detection limit of the existing rapid EBOV immunoassay. In a mock clinical trial, the sensor detects sGP-spiked human plasma samples at two times the limit of detection with 95.8% sensitivity. The results combined highlight the nanosensor's extraordinary capability of detecting EBOV antigen at ultralow concentration compared to existing immunoassay methods. It is a promising next-generation bioassay platform for early-stage disease diagnosis and pathogen detection for both public health and national security applications.
Collapse
Affiliation(s)
- Faheng Zang
- Department of Electrical Engineering, Princeton University, Princeton, NJ, 08544, USA
| | - Zhijuan Su
- Department of Electrical Engineering, Princeton University, Princeton, NJ, 08544, USA
| | - Liangcheng Zhou
- Department of Electrical Engineering, Princeton University, Princeton, NJ, 08544, USA
| | - Krishnamurthy Konduru
- Laboratory of Emerging Pathogens, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA
| | - Gerardo Kaplan
- Laboratory of Emerging Pathogens, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA
| | - Stephen Y Chou
- Department of Electrical Engineering, Princeton University, Princeton, NJ, 08544, USA
| |
Collapse
|
33
|
Yokose T, Obara H, Shinoda M, Nakano Y, Kitago M, Yagi H, Abe Y, Yamada Y, Matsubara K, Oshima G, Hori S, Ibuki S, Higashi H, Masuda Y, Hayashi M, Mori T, Kawaida M, Fujimura T, Hoshino K, Kameyama K, Kuroda T, Kitagawa Y. Colon perforation due to antigenemia-negative cytomegalovirus gastroenteritis after liver transplantation: A case report and review of literature. World J Gastroenterol 2019; 25:1899-1906. [PMID: 31057303 PMCID: PMC6478612 DOI: 10.3748/wjg.v25.i15.1899] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/10/2019] [Revised: 03/03/2019] [Accepted: 03/16/2019] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Cytomegalovirus (CMV) remains a critical complication after solid-organ transplantation. The CMV antigenemia (AG) test is useful for monitoring CMV infection. Although the AG-positivity rate in CMV gastroenteritis is known to be low at onset, almost all cases become positive during the disease course. We treated a patient with transverse colon perforation due to AG-negative CMV gastroenteritis, following a living donor liver transplantation (LDLT).
CASE SUMMARY The patient was a 52-year-old woman with decompensated liver cirrhosis as a result of autoimmune hepatitis who underwent a blood-type compatible LDLT with her second son as the donor. On day 20 after surgery, upper and lower gastrointestinal endoscopy (GE) revealed multiple gastric ulcers and transverse colon ulcers. The biopsy tissue immunostaining confirmed a diagnosis of CMV gastroenteritis. On day 28 after surgery, an abdominal computed tomography revealed transverse colon perforation, and simple lavage and drainage were performed along with an urgent ileostomy. Although the repeated remission and aggravation of CMV gastroenteritis and acute cellular rejection made the control of immunosuppression difficult, the upper GE eventually revealed an improvement in the gastric ulcers, and the biopsy samples were negative for CMV. The CMV-AG test remained negative, therefore, we had to evaluate the status of the CMV infection on the basis of the clinical symptoms and GE.
CONCLUSION This case report suggests a monitoring method that could be useful for AG-negative CMV gastroenteritis after a solid-organ transplantation.
Collapse
Affiliation(s)
- Takahiro Yokose
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Hideaki Obara
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Masahiro Shinoda
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Yutaka Nakano
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Minoru Kitago
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Hiroshi Yagi
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Yuta Abe
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Yohei Yamada
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Kentaro Matsubara
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Go Oshima
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Shutaro Hori
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Sho Ibuki
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Hisanobu Higashi
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Yuki Masuda
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Masanori Hayashi
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Takehiko Mori
- Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Miho Kawaida
- Department of Pathology, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Takumi Fujimura
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Ken Hoshino
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Kaori Kameyama
- Department of Pathology, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Tatsuo Kuroda
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| | - Yuko Kitagawa
- Department of Surgery, Keio University School of Medicine, Tokyo 1608582, Japan
| |
Collapse
|
34
|
Cui M, Fang Q, Zheng J, Shu Z, Chen Y, Fan Y, Zhao J, Wood C, Zhang T, Zeng Y. Kaposi's sarcoma-associated herpesvirus seropositivity is associated with type 2 diabetes mellitus: A case-control study in Xinjiang, China. Int J Infect Dis 2019; 80:73-79. [PMID: 30639407 DOI: 10.1016/j.ijid.2019.01.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2018] [Revised: 12/24/2018] [Accepted: 01/04/2019] [Indexed: 02/07/2023] Open
Abstract
OBJECTIVE To assess the potential relationship between Kaposi's sarcoma-associated herpesvirus (KSHV) infection and type 2 diabetes mellitus (DM-2) in Xinjiang, China. METHODS A case-control study of consecutively included DM-2 patients and normal controls was conducted among the Uygur and Han populations in Xinjiang Uygur Autonomous Region, China. Blood samples were collected and KSHV seroprevalence, antibody titers, and viral load were investigated. Logistic regression analysis and multiple linear regression analysis were applied to explore determinants of the main outcome measures. RESULTS A total of 324 patients with DM-2 and 376 normal controls were included. The seroprevalence of KSHV was 49.1% (95% confidence interval (CI) 43.6-54.5%) for diabetic patients and 23.7% (95% CI 19.4-28.0%) for the control group. After adjusting for variables of ethnicity, sex, body mass index, occupation, educational level, marital status, age, and smoking and alcohol consumption habits, the association between DM-2 and KSHV infection still existed (odds ratio (OR) 2.94, 95% CI 2.05-4.22), and the risk of KSHV infection increased with glucose concentration (OR 1.35, 95% CI 1.21-1.51). KSHV was more likely to express both the latent and lytic antigens in diabetic patients (latent: OR 3.27, 95% CI 2.25-4.75; lytic: OR 3.99, 95% CI 2.68-5.93). Antibody titers and viral load increased in patients with higher blood glucose levels (p<0.001). CONCLUSIONS Patients with DM-2 have an elevated risk of KSHV infection. Both antibody titers and viral load increased with blood glucose levels.
Collapse
Affiliation(s)
- Meng Cui
- Key Laboratory of Xinjiang Endemic and Ethnic Disease and Department of Biochemistry, School of Medicine, Shihezi University, Shihezi 832000, China
| | - Qiwen Fang
- Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China
| | - Jun Zheng
- Department of Stomatology, The First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi 832000, China
| | - Zhanjun Shu
- Division of AIDS Research, National Traditional Chinese Medicine Clinical Research Bases in Xinjiang, Urumqi 830000, China; The Sixth People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830013, China
| | - Yin Chen
- The Sixth People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830013, China
| | - Yage Fan
- Key Laboratory of Xinjiang Endemic and Ethnic Disease and Department of Biochemistry, School of Medicine, Shihezi University, Shihezi 832000, China
| | - Juan Zhao
- Key Laboratory of Xinjiang Endemic and Ethnic Disease and Department of Biochemistry, School of Medicine, Shihezi University, Shihezi 832000, China
| | - Charles Wood
- Nebraska Center of Virology and the School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA
| | - Tiejun Zhang
- Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China.
| | - Yan Zeng
- Key Laboratory of Xinjiang Endemic and Ethnic Disease and Department of Biochemistry, School of Medicine, Shihezi University, Shihezi 832000, China.
| |
Collapse
|
35
|
Mbewana S, Meyers AE, Weber B, Mareledwane V, Ferreira ML, Majiwa PAO, Rybicki EP. Expression of Rift Valley fever virus N-protein in Nicotiana benthamiana for use as a diagnostic antigen. BMC Biotechnol 2018; 18:77. [PMID: 30537953 PMCID: PMC6290525 DOI: 10.1186/s12896-018-0489-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2017] [Accepted: 11/29/2018] [Indexed: 12/01/2022] Open
Abstract
BACKGROUND Rift Valley fever virus (RVFV), the causative agent of Rift Valley fever, is an enveloped single-stranded negative-sense RNA virus in the genus Phlebovirus, family Bunyaviridae. The virus is spread by infected mosquitoes and affects ruminants and humans, causing abortion storms in pregnant ruminants, high neonatal mortality in animals, and morbidity and occasional fatalities in humans. The disease is endemic in parts of Africa and the Arabian Peninsula, but is described as emerging due to the wide range of mosquitoes that could spread the disease into non-endemic regions. There are different tests for determining whether animals are infected with or have been exposed to RVFV. The most common serological test is antibody ELISA, which detects host immunoglobulins M or G produced specifically in response to infection with RVFV. The presence of antibodies to RVFV nucleocapsid protein (N-protein) is among the best indicators of RVFV exposure in animals. This work describes an investigation of the feasibility of producing a recombinant N-protein in Nicotiana benthamiana and using it in an ELISA. RESULTS The human-codon optimised RVFV N-protein was successfully expressed in N. benthamiana via Agrobacterium-mediated infiltration of leaves. The recombinant protein was detected as monomers and dimers with maximum protein yields calculated to be 500-558 mg/kg of fresh plant leaves. The identity of the protein was confirmed by liquid chromatography-mass spectrometry (LC-MS) resulting in 87.35% coverage, with 264 unique peptides. Transmission electron microscopy revealed that the protein forms ring structures of ~ 10 nm in diameter. Preliminary data revealed that the protein could successfully differentiate between sera of RVFV-infected sheep and from sera of those not infected with the virus. CONCLUSIONS To the best of our knowledge this is the first study demonstrating the successful production of RVFV N-protein as a diagnostic reagent by Agrobacterium-mediated transient heterologous expression in N. benthamiana. Preliminary testing of the antigen showed its ability to distinguish RVFV-positive animal sera from RVFV negative animal sera when used in an enzyme linked immunosorbent assay (ELISA). The cost-effective, scalable and simple production method has great potential for use in developing countries where rapid diagnosis of RVFV is necessary.
Collapse
Affiliation(s)
- Sandiswa Mbewana
- Biopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, 6503200115084, Rondebosch, Cape Town, 7700 South Africa
| | - Ann E. Meyers
- Biopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, 6503200115084, Rondebosch, Cape Town, 7700 South Africa
| | - Brandon Weber
- Structural Biology Research Unit, University of Cape Town, P Bag X3, Rondebosch, 7700 South Africa
| | - Vuyokazi Mareledwane
- ARC-Onderstepoort Veterinary Institute, 100 Old Southpan Road, Onderstepoort, 0110 South Africa
| | - Maryke L. Ferreira
- ARC-Onderstepoort Veterinary Institute, 100 Old Southpan Road, Onderstepoort, 0110 South Africa
| | - Phelix A. O. Majiwa
- ARC-Onderstepoort Veterinary Institute, 100 Old Southpan Road, Onderstepoort, 0110 South Africa
| | - Edward P. Rybicki
- Biopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, 6503200115084, Rondebosch, Cape Town, 7700 South Africa
- Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Anzio Road, Observatory, Cape Town, 7925 South Africa
| |
Collapse
|
36
|
Abstract
Singapore experienced its first documented Zika virus outbreak in 2016. We identified clinical and laboratory parameters that increase the probability for Zika or dengue virus infection. Early during the illness, combinations of key parameters obtained through clinical assessment and hematologic tests can help distinguish between these infections.
Collapse
|
37
|
Nunes PCG, Nogueira RMR, Heringer M, Chouin-Carneiro T, Damasceno Dos Santos Rodrigues C, de Filippis AMB, Lima MDRQ, Dos Santos FB. NS1 Antigenemia and Viraemia Load: Potential Markers of Progression to Dengue Fatal Outcome? Viruses 2018; 10:E326. [PMID: 29903980 PMCID: PMC6024368 DOI: 10.3390/v10060326] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2018] [Revised: 02/22/2018] [Accepted: 03/01/2018] [Indexed: 01/29/2023] Open
Abstract
Dengue is a worldwide problem characterized by a multifactorial pathogenesis. Considering the viral components, it is known that high viremia or high levels of the secreted nonstructural protein 1 (NS1) may be associated with a more severe disease. We aimed to characterize the NS1 antigenemia and viremia in dengue fatal and non-fatal cases, as potential markers of progression to a fatal outcome. NS1 antigenemia and viremia were determined in Brazilian dengue fatal cases (n = 40) and non-fatal cases (n = 40), representative of the four dengue virus (DENV) serotypes. Overall, the fatal cases presented higher NS1 levels and viremia. Moreover, the fatal cases from secondary infections showed significantly higher NS1 levels than the non-fatal ones. Here, irrespective of the disease outcome, DENV-1 cases presented higher NS1 levels than the other serotypes. However, DENV-2 and DENV-4 fatal cases had higher NS1 antigenemia than the non-fatal cases with the same serotype. The viremia in the fatal cases was higher than in the non-fatal ones, with DENV-3 and DENV-4 presenting higher viral loads. Viral components, such as NS1 and viral RNA, may be factors influencing the disease outcome. However, the host immune status, comorbidities, and access to adequate medical support cannot be ruled out as interfering in the disease outcome.
Collapse
Affiliation(s)
- Priscila Conrado Guerra Nunes
- Viral Immunology Laboratory (LIV), Oswaldo Cruz Institute-FIOCRUZ, Avenida Brasil, 4365. Manguinhos, Rio de Janeiro 21040-360, Brazil.
- Flavivirus Laboratory (LABFLA), Oswaldo Cruz Institute-FIOCRUZ, Avenida Brasil, 4365. Manguinhos, Rio de Janeiro 21040-360, Brazil.
| | - Rita Maria Ribeiro Nogueira
- Flavivirus Laboratory (LABFLA), Oswaldo Cruz Institute-FIOCRUZ, Avenida Brasil, 4365. Manguinhos, Rio de Janeiro 21040-360, Brazil.
| | - Manoela Heringer
- Viral Immunology Laboratory (LIV), Oswaldo Cruz Institute-FIOCRUZ, Avenida Brasil, 4365. Manguinhos, Rio de Janeiro 21040-360, Brazil.
| | - Thaís Chouin-Carneiro
- Viral Immunology Laboratory (LIV), Oswaldo Cruz Institute-FIOCRUZ, Avenida Brasil, 4365. Manguinhos, Rio de Janeiro 21040-360, Brazil.
- Hematozoa Transmittors Mosquitoes Laboratory, Oswaldo Cruz Institute, Rio de Janeiro 21040-360, Brazil.
| | | | - Ana Maria Bispo de Filippis
- Flavivirus Laboratory (LABFLA), Oswaldo Cruz Institute-FIOCRUZ, Avenida Brasil, 4365. Manguinhos, Rio de Janeiro 21040-360, Brazil.
| | - Monique da Rocha Queiroz Lima
- Viral Immunology Laboratory (LIV), Oswaldo Cruz Institute-FIOCRUZ, Avenida Brasil, 4365. Manguinhos, Rio de Janeiro 21040-360, Brazil.
| | - Flávia Barreto Dos Santos
- Viral Immunology Laboratory (LIV), Oswaldo Cruz Institute-FIOCRUZ, Avenida Brasil, 4365. Manguinhos, Rio de Janeiro 21040-360, Brazil.
| |
Collapse
|
38
|
Wani SA, Sahu AR, Saxena S, Rajak KK, Saminathan M, Sahoo AP, Kanchan S, Pandey A, Mishra B, Muthuchelvan D, Tiwari AK, Mishra BP, Singh RK, Gandham RK. Expression kinetics of ISG15, IRF3, IFNγ, IL10, IL2 and IL4 genes vis-a-vis virus shedding, tissue tropism and antibody dynamics in PPRV vaccinated, challenged, infected sheep and goats. Microb Pathog 2018; 117:206-218. [PMID: 29476787 DOI: 10.1016/j.micpath.2018.02.027] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2017] [Revised: 01/18/2018] [Accepted: 02/12/2018] [Indexed: 11/16/2022]
Abstract
Here, we studied the in vivo expression of Th1 (IL2 and IFN gamma) and Th2 (IL4 and IL10) - cytokines and antiviral molecules - IRF3 and ISG15 in peripheral blood mononuclear cells in relation to antigen and antibody dynamics under Peste des petits ruminants virus (PPRV) vaccination, infection and challenge in both sheep and goats. Vaccinated goats were seropositive by 9 days post vaccination (dpv) while in sheep idiosyncratic response was observed between 9 and 14 dpv for different animals. Expression of PPRV N gene was not detected in PBMCs of vaccinated and vaccinated challenged groups of both species, but was detected in unvaccinated infected PBMCs at 9 and 14 days post infection. The higher viral load at 9 dpi coincided with the peak clinical signs of the disease. The peak in viral replication at 9 dpi correlated with significant expression of antiviral molecules IRF3, ISG15 and IFN gamma in both the species. With the progression of disease, the decrease in N gene expression also correlated with the decrease in expression of IRF3, ISG15 and IFN gamma. In the unvaccinated infected animals ISG15, IRF3, IFN gamma and IL10 expression was higher than vaccinated animals. The IFN gamma expression predominated over IL4 in both vaccinated and infected animals with the infected exhibiting a stronger Th1 response. The persistent upregulation of this antiviral molecular signature - ISG15 and IRF3 even after 2 weeks post vaccination, presumably reflects the ongoing stimulation of innate immune cells.
Collapse
Affiliation(s)
- Sajad Ahmad Wani
- Division of Veterinary Biotechnology, ICAR-IVRI, Izatnagar, Bareilly, UP, 243122, India
| | - Amit Ranjan Sahu
- Division of Veterinary Biotechnology, ICAR-IVRI, Izatnagar, Bareilly, UP, 243122, India
| | - Shikha Saxena
- Division of Veterinary Biotechnology, ICAR-IVRI, Izatnagar, Bareilly, UP, 243122, India
| | - Kaushal Kishor Rajak
- Division of Biological Products, ICAR-IVRI, Izatnagar, Bareilly, UP, 243122, India
| | - M Saminathan
- Division of Veterinary Pathology, ICAR-IVRI, Izatnagar, Bareilly, UP, 243122, India
| | - Aditya Prasad Sahoo
- Division of Veterinary Biotechnology, ICAR-IVRI, Izatnagar, Bareilly, UP, 243122, India
| | - Sonam Kanchan
- Division of Veterinary Biotechnology, ICAR-IVRI, Izatnagar, Bareilly, UP, 243122, India
| | - Aruna Pandey
- Division of Veterinary Biotechnology, ICAR-IVRI, Izatnagar, Bareilly, UP, 243122, India
| | - Bina Mishra
- Division of Biological Products, ICAR-IVRI, Izatnagar, Bareilly, UP, 243122, India
| | - D Muthuchelvan
- Division of Virology, ICAR-IVRI, Mukteshwar Campus, Nainital, 263138, India
| | - Ashok Kumar Tiwari
- Division of Biological Standardization, ICAR-IVRI, Izatnagar, Bareilly, UP, 243122, India
| | - Bishnu Prasad Mishra
- Division of Veterinary Biotechnology, ICAR-IVRI, Izatnagar, Bareilly, UP, 243122, India
| | - Raj Kumar Singh
- Division of Veterinary Biotechnology, ICAR-IVRI, Izatnagar, Bareilly, UP, 243122, India
| | - Ravi Kumar Gandham
- Division of Veterinary Biotechnology, ICAR-IVRI, Izatnagar, Bareilly, UP, 243122, India.
| |
Collapse
|
39
|
Beader N, Kolarić B, Slačanac D, Tabain I, Vilibić-Čavlek T. Seroepidemiological Study of Epstein-Barr Virus in Different Population Groups in Croatia. Isr Med Assoc J 2018; 20:86-90. [PMID: 29431301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
BACKGROUND The Epstein-Barr virus (EBV) is one of the most common viruses found in humans, causing lifelong infection in up to 95% of the world population. OBJECTIVES To analyze the seroprevalence of EBV infection in different population groups in Croatia. METHODS During a 2 year period (2015-2016), a total of 2022 consecutive serum samples collected from Croatian residents were tested for the presence of EBV-specific viral capsid antigen (VCA) immunoglobulin M (IgM) and IgG antibodies using an enzyme-linked immunoassay. IgM/IgG-positive samples were further tested for IgG avidity. RESULTS The overall prevalence of EBV IgG antibodies was 91.4%. Females had significantly higher IgG seroprevalence than males (93.1% vs. 89.9%, P = 0.008). According to age, IgG seropositivity increased progressively from 59.6% in children age < 9 years to 98.3% in 30-39 year olds, and remained stable thereafter (P < 0.001). The IgG seroprevalence differed significantly among groups: 68.1% in children/adolescents and 95.9% in adults; multiple sclerosis (100%), hemodialysis patients (97.7%), heart transplant recipients (93.8%), hematological malignancies (91.2%), and Crohn's disease (88.5%), P < 0.001. IgM antibodies were detected in 9% of participants. Using IgG avidity, recent primary EBV infection was documented in 83.8% of IgM-positive subjects < 9 years old, 69.2% age 10-19, 33.3% age 20-29, and 3.6-4.2% > 40. All IgM positive participants > 40 years showed high IgG avidity. Logistic regression showed that age is associated with EBV IgG seropositivity. CONCLUSIONS EBV is widespread in the Croatian population. Older age appears to be the main risk factor for EBV seropositivity.
Collapse
Affiliation(s)
- Nataša Beader
- Department of Microbiology, School of Medicine, University of Zagreb, Zagreb, Croatia
- Department of Clinical and Molecular Microbiology, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Branko Kolarić
- Department for Social Medicine and Epidemiology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia
- Department of Epidemiology, Andrija Stampar Teaching Institute of Public Health, Zagreb Croatia
| | - Domagoj Slačanac
- Department of Microbiology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Irena Tabain
- Department of Virology, Croatian National Institute of Public Health, Zagreb, Croatia
| | - Tatjana Vilibić-Čavlek
- Department of Microbiology, School of Medicine, University of Zagreb, Zagreb, Croatia
- Department of Virology, Croatian National Institute of Public Health, Zagreb, Croatia
| |
Collapse
|
40
|
Tabery HM. Corneal Surface Changes in Thygeson's Superficial Punctate Keratitis: A Clinical and Noncontact Photomicrographic in Vivo Study in the Human Cornea. Eur J Ophthalmol 2018; 14:85-93. [PMID: 15134103 DOI: 10.1177/112067210401400201] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Purpose To elucidate mechanisms behind the morphology of Thygeson's superficial punctate keratitis (TSPK). METHODS Sixteen patients were examined with the slit lamp and photographed by noncontact photomicrography. The results were compared with morphology of epithelial keratitis in herpes simplex type 1 (HSV1), varicella zoster (VZV), and adenovirus type 8 (Ad8) infections, all previously studied by the same method, and with published histologic findings in TSPK. Results In the photographs, the corneal epithelium showed various numbers of abnormal subsurface cells measuring about 10 μm in diameter, present individually, in small groups, or aggregated in larger lesions (coarse lesions with the slit lamp). The surface epithelium was well preserved, except in larger lesions, which showed surface debris. The morphology was unlike HSV1 and VZV epithelial keratitis, but strongly resembled epithelial changes occurring in Ad8 infections on day 5, and later, after the onset of symptoms. CONCLUSIONS TSPK shows a more widespread epithelial involvement than suspected with the slit lamp. Its morphology seems to reflect an action of a noxious agent targeted at the deeper epithelial layers, with the appearance of abnormal cells as a result. These might represent invading inflammatory cells, damaged intraepithelial ones, or both. The coarse lesions visualize areas of major involvement showing discernible signs of cell destruction. The similarity to Ad8 keratitis suggests that the source of the noxious agent might be located outside the cornea. The morphology, in conjunction with clinical features, is compatible with an immunologically mediated injury. The etiology remains unknown.
Collapse
Affiliation(s)
- H M Tabery
- Department of Ophthalmology, Malmö University Hospital, Malmö, Sweden.
| |
Collapse
|
41
|
Gale TV, Horton TM, Grant DS, Garry RF. Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers. PLoS Negl Trop Dis 2017; 11:e0005943. [PMID: 28922385 PMCID: PMC5619842 DOI: 10.1371/journal.pntd.0005943] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Revised: 09/28/2017] [Accepted: 09/07/2017] [Indexed: 12/16/2022] Open
Abstract
Lassa fever afflicts tens of thousands of people in West Africa annually. The rapid progression of patients from febrile illness to fulminant syndrome and death provides incentive for development of clinical prognostic markers that can guide case management. The small molecule profile of serum from febrile patients triaged to the Viral Hemorrhagic Fever Ward at Kenema Government Hospital in Sierra Leone was assessed using untargeted Ultra High Performance Liquid Chromatography Mass Spectrometry. Physiological dysregulation resulting from Lassa virus (LASV) infection occurs at the small molecule level. Effects of LASV infection on pathways mediating blood coagulation, and lipid, amino acid, nucleic acid metabolism are manifest in changes in the levels of numerous metabolites in the circulation. Several compounds, including platelet activating factor (PAF), PAF-like molecules and products of heme breakdown emerged as candidates that may prove useful in diagnostic assays to inform better care of Lassa fever patients. Lassa fever afflicts tens of thousands of people in West Africa each year. The disease progresses rapidly, but there are no tests available to determine which patients are at high risk for dying. We measured the levels of small molecules in the blood of febrile patients with and without infection by LASV that presented to Kenema Government Hospital in Sierra Leone using Ultra High Performance Liquid Chromatography Mass Spectrometry (LCMS), which identifies compounds based on their precise mass. Computational analyses were used to identify compounds that differed in patients with an acute LASV infection, patients with evidence of prior exposure to LASV and patients with fever, but who did not have evidence of exposure to LASV. Several serum metabolites, including factors that are involved in blood clotting and breakdown products of heme, were identified that may prove useful in diagnostic assays that will inform better care of Lassa fever patients or development of therapeutic interventions.
Collapse
Affiliation(s)
- Trevor V. Gale
- Department of Microbiology and Immunology, Tulane University, New Orleans, Louisiana, United States of America
| | - Timothy M. Horton
- Department of Microbiology and Immunology, Tulane University, New Orleans, Louisiana, United States of America
| | - Donald S. Grant
- Viral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone
- Ministry of Health and Sanitation, Freetown, Sierra Leone
| | - Robert F. Garry
- Department of Microbiology and Immunology, Tulane University, New Orleans, Louisiana, United States of America
- Zalgen Labs, LLC, Germantown, Maryland, United States of America
- Tulane Center of Excellence, Global Viral Network, New Orleans, Louisiana, United States of America
- * E-mail:
| |
Collapse
|
42
|
Ahmad Qureshi EM, Tabinda AB, Vehra S. Sero-surveillance of dengue in the city Lahore, Pakistan. J PAK MED ASSOC 2017; 67:1173-1179. [PMID: 28839300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVE To conduct sero-surveillance of dengue cases, and to find out the demographic and socio-economic status of dengue patients. METHODS This community-based, cross-sectional, descriptive study was conducted at the Institute of Public Health, Lahore, Pakistan, from July to December each year in 2011, 2012 and 2013, and comprised patients suspected to have dengue. Blood samples of dengue patients in five randomly selected union councils of the 10 towns of the city were subjected to the dengue test. Information about demographic and socio-economic characteristics was obtained with the help of pre-tested semi-structured questionnaire. SPSS 16 was used for data analysis. RESULTS Of the 5,544 dengue patients, 5.263 (94.9%) patients were diagnosed in 2011, followed by 25(0.45%) and 256(4.6%) in 2012 and 2013, respectively. Sero-surveillance of these dengue patients in 2011 showed that on an average 3,094 (58.79%) cases had primary infection, 1,506 (28.61%) had old infection, while only 663 (12.6%) had secondary infection. Similar pattern was observed in 2012 and 2013. It was found that 2,379 (42.9%) participants were aged between 15-30 years and 2,203 (39.7%) between 31-45 years. Besides, 3,618 (65.3%) participants were males and 1,926 (34.7%) females. Also, 2,865 (51.4%) participants were labourers, 2,746 (49.5%) and 2,260 (40.7%) were educated up to primary and secondary levels, respectively. Although sporadic dengue cases were recorded from July to December, most of the cases were observed in late rainy and early post-rainy seasons. CONCLUSIONS The incidence of dengue was highest in people of 15-45years of age, particularly males, labourers and those with low income.
Collapse
Affiliation(s)
| | - Amtul Bari Tabinda
- Sustainable Development Study Centre, Government College University, Lahore, Pakistan
| | - Seemal Vehra
- Government Post Graduate College for Women, Lahore, Pakistan
| |
Collapse
|
43
|
Chotun N, Preiser W, van Rensburg CJ, Fernandez P, Theron GB, Glebe D, Andersson MI. Point-of-care screening for hepatitis B virus infection in pregnant women at an antenatal clinic: A South African experience. PLoS One 2017; 12:e0181267. [PMID: 28732085 PMCID: PMC5521792 DOI: 10.1371/journal.pone.0181267] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Accepted: 06/28/2017] [Indexed: 01/21/2023] Open
Abstract
BACKGROUND & AIMS Elimination of HIV and syphilis mother-to-child transmission (MTCT) has received much attention but little consideration has been given to the possibility of elimination of HBV MTCT. In sub-Saharan Africa, HBV vertical transmission continues to be reported and it remains an important public health problem. This study aimed to assess the feasibility of screening pregnant women for HBV using a point-of-care (POC) test and implementing interventions to prevent HBV MTCT. METHODS In this observational prospective cohort study, HIV-uninfected pregnant women who consented to testing were screened for HBV using a rapid POC test for HBsAg. Positive results were laboratory-confirmed and tested for HBV DNA and serological markers. Women with viral loads ≥ 20 000 IU/ml received tenofovir (TDF) treatment and all infants received birth-dose HBV vaccine. Two blood samples collected six months apart from HBV-exposed infants within their first year of life were tested for HBV DNA. RESULTS Of 144 women who were approached, 134 consented to participating (93% acceptance rate of HBV POC test). Six women tested positive for HBsAg (4.5%; 95% CI 0.99%-8.01%), all confirmed by laboratory testing. Two mothers, M1 and M4, were treated with TDF during their third trimester of pregnancy. Six HBV-exposed infants received the HBV vaccine within 24 hours of birth, of whom two were lost to follow-up and four (including the two born to M1 and M4) had undetectable levels of HBV DNA when tested at the two time points. CONCLUSION We found that HBV screening using POC testing fulfilled the criteria considered necessary for implementation. It has acceptable performance, is inexpensive, reliable, and was well accepted by the study participants. Screening pregnant women as part of the HBV MTCT prevention strategy is therefore feasible in a South African clinical setting.
Collapse
Affiliation(s)
- Nafiisah Chotun
- Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa
| | - Wolfgang Preiser
- Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa
- National Health Laboratory Service (NHLS), Tygerberg Hospital, Tygerberg, South Africa
| | | | - Pedro Fernandez
- Division of Urology, Department of Surgical Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa
| | - Gerhard Barnard Theron
- Department of Obstetrics and Gynaecology, Stellenbosch University, Tygerberg, Cape Town, South Africa
| | - Dieter Glebe
- Institute of Medical Virology, National Reference Centre for Hepatitis-B and D Viruses, Justus-Liebig-University Giessen, German Centre for Infection Research (DZIF), Giessen, Germany
| | - Monique Ingrid Andersson
- Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa
- Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
| |
Collapse
|
44
|
Lum FM, Lin C, Susova OY, Teo TH, Fong SW, Mak TM, Lee LK, Chong CY, Lye DCB, Lin RTP, Merits A, Leo YS, Ng LFP. A Sensitive Method for Detecting Zika Virus Antigen in Patients' Whole-Blood Specimens as an Alternative Diagnostic Approach. J Infect Dis 2017; 216:182-190. [PMID: 28586426 PMCID: PMC5853302 DOI: 10.1093/infdis/jix276] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2017] [Accepted: 06/02/2017] [Indexed: 01/15/2023] Open
Abstract
Background Epidemics caused by the reemergence of Zika virus (ZIKV) warrant the need to develop new diagnostic measures to complement currently used detection methods. In this study, we explored the detection of ZIKV antigen in a defined leukocyte subset from patients' whole-blood specimens. Methods Whole-blood samples were obtained at the acute and early convalescent phases from ZIKV-infected patients during the Singapore outbreak in August-September 2016. Presence of ZIKV antigen was determined by flow cytometry staining for intracellular ZIKV NS3, using a ZIKV-specific polyclonal antibody. The presence of ZIKV antigen was determined in CD45+CD14+ monocytes. Results Data showed that ZIKV NS3 antigen could be detected in CD45+CD14+ monocytes. The levels of detection were further categorized into 3 groups: high (positivity among >40% of monocytes), moderate (positivity among 10%-40%), and low (positivity among <10%). While a majority of patients showed a decrease in the amount of ZIKV antigen detected at later time points, some patients displayed higher levels as the disease progressed. Conclusions Our data highlights an alternative approach in using flow cytometry as a sensitive method for detecting ZIKV antigen in whole blood. Importantly, it further confirms the role of CD14+ monocytes as an important cellular target for ZIKV infection during the viremic phase.
Collapse
Affiliation(s)
- Fok-Moon Lum
- Singapore Immunology Network, Agency for Science, Technology and Research
| | - Cui Lin
- National Public Health Laboratory, Ministry of Health
| | - Olga Y Susova
- Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Moscow
| | - Teck-Hui Teo
- Singapore Immunology Network, Agency for Science, Technology and Research
| | - Siew-Wai Fong
- Singapore Immunology Network, Agency for Science, Technology and Research
- Department of Biological Science
| | - Tze-Minn Mak
- National Public Health Laboratory, Ministry of Health
| | - Linda Kay Lee
- Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital
| | | | - David C B Lye
- Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital
| | | | - Andres Merits
- Institute of Technology, University of Tartu, Estonia
| | - Yee-Sin Leo
- Saw Swee Hock School of Public Health, National University of Singapore
- Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
| | - Lisa F P Ng
- Singapore Immunology Network, Agency for Science, Technology and Research
- Institute of Infection and Global Health, University of Liverpool, United Kingdom
| |
Collapse
|
45
|
Chen HF, Zhang LL, Fang YB, Chen M, Guo C, Yi HL, Tao MT, Li Y, Dai CF. [A preliminary study on the disappearance time of influenza virus antigen]. Zhongguo Dang Dai Er Ke Za Zhi 2017; 19:564-566. [PMID: 28506350 PMCID: PMC7389127 DOI: 10.7499/j.issn.1008-8830.2017.05.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 12/04/2016] [Accepted: 02/05/2017] [Indexed: 06/07/2023]
Abstract
OBJECTIVE To investigate the antigen clearance time, time to symptom disappearance, and the association between them using immunofluorescence assay for dynamic monitoring of influenza virus antigen in children with influenza. METHODS A total of 1 063 children suspected of influenza who visited the Hunan People's Hospital from March to April, 2016 were enrolled. The influenza A/B virus antigen detection kit (immunofluorescence assay) was used for influenza virus antigen detection. The children with positive results were given oseltamivir as the antiviral therapy and were asked to re-examine influenza virus antigen at 5, 5-7, and 7 days after onset. RESULTS Of all children suspected of influenza, 560 (52.68%) had an influenza virus infection. A total of 215 children with influenza virus infection were followed up. The clearance rate of influenza virus antigen was 9.8% (21 cases) within 5 days after onset. The cumulative clearance rate of influenza virus antigen was 32.1% (69 cases) within 5-7 days, and 98.1% (211 cases) within 7-10 days after onset. Among these children, 6 children (2.8%) achieved the improvement in clinical symptoms within 3 days after onset. The cumulative rate of symptom improvement was 84.7% (182 cases) within 3-5 days after onset, and 100% achieved the improvement after 5 days of onset. CONCLUSIONS The time to improvement in symptoms after treatment is earlier than antigen clearance time. Almost all of the children achieve influenza virus antigen clearance 7-10 days after onset. Therefore, it is relatively safe for children to go back to school within 7-10 days after onset when symptoms disappear.
Collapse
Affiliation(s)
- Hao-Feng Chen
- Pediatric Medical Center, Hunan People's Hospital, Changsha 410005, China.
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Tandon P, James P, Cordeiro E, Mallick R, Shukla T, McCurdy JD. Diagnostic Accuracy of Blood-Based Tests and Histopathology for Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2017; 23:551-560. [PMID: 28296820 DOI: 10.1097/mib.0000000000001073] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND It is unclear if traditional histopathology and noninvasive blood-based tests are sufficiently accurate to detect cytomegalovirus (CMV) reactivation in inflammatory bowel disease. Therefore, we assessed the diagnostic accuracy of these tests compared with immunohistochemistry (IHC) and tissue polymerase chain reaction (PCR). METHODS A systematic search of electronic databases was performed from inception through January 2016 for observational studies comparing diagnostic tests for CMV reactivation in inflammatory bowel disease. IHC and tissue PCR were considered reference standards and were used to evaluate the accuracy of blood-based tests and hematoxylin and eosin histopathology. Weighted summary estimates with 95% confidence intervals (CIs) were calculated using bivariate analysis. RESULTS Nine studies examined the accuracy of blood-based tests for predicting colonic CMV reactivation: 5 studies by pp65 antigenemia and 4 studies by blood PCR. The overall sensitivity was 50.8% (95% CI, 19.9-81.6), the specificity was 99.9% (95% CI, 99-100), and the positive predictive value was 83.8% (95% CI, 58.6-95.0). The sensitivities of pp65 and blood PCR were 39.7% (95% CI, 27.4-52.1) and 60.0% (95% CI, 46.5-73.5), respectively. Nine studies examined the sensitivity of histopathology. The overall sensitivity was 12.5% (95% CI, 3.6-21.4), 34.6% by IHC (95% CI, 13.8-55.4), and 4.7% by tissue PCR (95% CI, 1.2-17.1). CONCLUSIONS Although blood-based tests seem to predict colonic CMV reactivation, they are insensitive tests. Similarly, histopathology has poor sensitivity for detecting colonic CMV. In agreement with current guidelines, these tests should not replace IHC or tissue PCR for detecting CMV reactivation in inflammatory bowel disease.
Collapse
Affiliation(s)
- Parul Tandon
- *Division of Gastroenterology and Hepatology, The Ottawa Hospital, Ottawa, Ontario, Canada; †Division of General Surgery, The Ottawa Hospital, Ottawa, Ontaro, Canada; and ‡Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
| | | | | | | | | | | |
Collapse
|
47
|
Hasan Z, Razzak S, Farhan M, Rahim M, Islam N, Samreen A, Khan E. Increasing usage of rapid diagnostics for Dengue virus detection in Pakistan. J PAK MED ASSOC 2017; 67:548-551. [PMID: 28420913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVE To evaluate the trends in usage of dengue virus diagnostics in Pakistan. METHODS This retrospective study was conducted at the Aga Khan University Hospital, Karachi, and comprised data for specimens tested for dengue virus from January 2012 to December 2015. Test for dengue virus ribonucleic acid by reverse transcription polymerase chain reaction, dengue virus antigen by immunochromatic assay and for human immunoglobulin M against dengue virus by enzyme-linked immunosorbent assay were reviewed. SPSS 17 was used for data analysis. RESULTS Overall, 33,577 specimens tested for dengue virus. Of them, 11,995 (35.7%) were positive. among them, 1,039(8.66%) were reported in 2012; 5,791(48.28%) in 2013; 1,027(8.56%) in 2014; and 4,138(34.49%) in 2015. In 2012, 966(93%) of the positive samples were diagnosed by immunoglobulin M-based method and 73(7%) by non-structural protein-1 antigen. In 2013, 4,401(76%) samples were tested positive by immunoglobulin M, 1,332(23%) by antigen and 58(1%) by polymerase chain reaction. The trend continued in 2014, but in 2015, 2,111(51%) of all dengue positive tests were determined by antigen testing, 1,969(47.6%) by immunoglobulin M and 58(1.4%) by polymerase chain reaction. CONCLUSIONS There was a shift in usage of direct virus identification for rapid diagnosis of dengue virus compared with host immunoglobulin M testing.
Collapse
|
48
|
Food and Drug Administration, HHS. Microbiology Devices; Reclassification of Influenza Virus Antigen Detection Test Systems Intended for Use Directly With Clinical Specimens. Final order. Fed Regist 2017; 82:3609-19. [PMID: 28102980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The Food and Drug Administration (FDA) is reclassifying antigen based rapid influenza virus antigen detection test systems intended to detect influenza virus directly from clinical specimens that are currently regulated as influenza virus serological reagents from class I into class II with special controls and into a new device classification regulation.
Collapse
|
49
|
Kawle AP, Nayak AR, Bhullar SS, Borkar SR, Patankar SD, Daginawala HF, Singh LR, Kashyap RS. Seroprevalence and clinical manifestations of chikungunya virus infection in rural areas of Chandrapur, Maharashtra, India. J Vector Borne Dis 2017; 54:35-43. [PMID: 28352044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023] Open
Abstract
BACKGROUND & OBJECTIVES Chikungunya virus (CHIKV) infection has recently witnessed re-emergence, affecting rural areas of India with high morbidity rates. This prospective study was conducted to evaluate seroprevalence and clinical manifestation in targeted villages reporting cases of CHIKV infection. METHODS A total of 482 patients were recruited from Kalmana and Kothari villages of Ballarpur; Chandrapur district of Maharashtra state, India during CHIKV outbreaks in 2011-12. The serum samples from infected CHIKV patients were simultaneously screened through ELISA for detection of antigen and antibodies (IgM and IgG). Chi-square analysis was used to evaluate differences in seropositivity between age, gender and clinical manifestations of CHIKV. RESULTS Out of 482 enrolled participants, 197 (41%) males and 285 (59%) females were aged between 5 and 92 yr. The clinical manifestations such as small joint pain (80%), neck stiffness (75%), fever (49%) and large joint pain (47%) were observed amongst CHIKV infected subjects. Mucocutaneous rashes (91%) on knees (71%), feet (56%), fingers and palms (54%) were also observed. Overall, seroprevalence of CHIKV infection was found to be 46% in infected participants during the epidemic period. Among risk factors, ageing and female gender was strongly associated with a raised seroprevalence of CHIKV infection along with symptoms such as rashes, small joints pain and neck stiffness. INTERPRETATION & CONCLUSION This study reported high seroprevalence rates of CHIKV infection in targeted popula- tions, suggesting its re-emergence in rural India. Proper surveillance is, therefore, necessary to minimize re-emergence and in controlling these impending and sporadic outbreaks.
Collapse
Affiliation(s)
- Anuja P Kawle
- Biochemistry Research Centre, Central India Institute of Medical Sciences, Nagpur, India
| | - Amit R Nayak
- Biochemistry Research Centre, Central India Institute of Medical Sciences, Nagpur, India
| | - Shradha S Bhullar
- Biochemistry Research Centre, Central India Institute of Medical Sciences, Nagpur, India
| | - Smita R Borkar
- Biochemistry Research Centre, Central India Institute of Medical Sciences, Nagpur, India
| | | | - Hatim F Daginawala
- Biochemistry Research Centre, Central India Institute of Medical Sciences, Nagpur, India
| | - Lokendra R Singh
- Biochemistry Research Centre, Central India Institute of Medical Sciences, Nagpur, India
| | - Rajpal S Kashyap
- Biochemistry Research Centre, Central India Institute of Medical Sciences, Nagpur, India
| |
Collapse
|
50
|
Zagórowicz E, Bugajski M, Wieszczy P, Pietrzak A, Magdziak A, Mróz A. Cytomegalovirus Infection in Ulcerative Colitis is Related to Severe Inflammation and a High Count of Cytomegalovirus-positive Cells in Biopsy Is a Risk Factor for Colectomy. J Crohns Colitis 2016; 10:1205-11. [PMID: 26971053 DOI: 10.1093/ecco-jcc/jjw071] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND AND AIMS Cytomegalovirus [CMV] infection often reactivates in the course of inflammatory bowel disease, but the significance of this remains disputable. Our aim was to evaluate whether severity of CMV colitis is associated with colectomy risk in ulcerative colitis [UC] patients. The secondary aim was to evaluate agreement between immunohistochemistry [IHC] and blood CMV polymerase chain reaction [PCR]. METHODS UC patients with CMV assessment of the colon, hospitalised in a referral unit between 2005 and 2012 were retrospectively identified. The course and severity of the disease were analysed, with inflammation graded histologically across the range 0-3. The numbers of CMV IHC-positive cells per biopsy section were counted, and results for blood CMV PCR were also retrieved. Data on colectomies were also collected. RESULTS Of 141 patients, 95 were analysed, with 33 found to be CMV IHC-positive and 62 negative. The colectomy risk was significantly higher in patients with ≥ 5 IHC-positive cells, as opposed to those with none or less than 5 [p = 0.014] with median follow-up of 1.9 and 3.2 years, respectively. The CMV IHC-positive patients had lower haemoglobin [median 11.0g/dl vs 12.0; p = 0.028] and albumin [median 29.5g/l vs 33.1; p = 0.038] levels and more intense histological inflammation [p = 0.020] compared with CMV IHC-negative patients. There was substantial agreement between IHC and blood PCR [Cohen's kappa coefficient 0.72]. CONCLUSIONS Five or more CMV IHC-positive cells per biopsy section were indicative of a greater colectomy risk. CMV infection was related to more severe inflammation. Blood CMV PCR is a useful tool in UC.
Collapse
Affiliation(s)
- Edyta Zagórowicz
- Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Department of Oncological Gastroenterology, Warsaw, Poland Medical Centre for Postgraduate Education, Department of Gastroenterology, Hepatology and Clinical Oncology, Warsaw, Poland
| | - Marek Bugajski
- Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Department of Oncological Gastroenterology, Warsaw, Poland Medical Centre for Postgraduate Education, Department of Gastroenterology, Hepatology and Clinical Oncology, Warsaw, Poland
| | - Paulina Wieszczy
- Medical Centre for Postgraduate Education, Department of Gastroenterology, Hepatology and Clinical Oncology, Warsaw, Poland
| | - Anna Pietrzak
- Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Department of Oncological Gastroenterology, Warsaw, Poland Medical Centre for Postgraduate Education, Department of Gastroenterology, Hepatology and Clinical Oncology, Warsaw, Poland
| | - Agnieszka Magdziak
- Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Department of Microbiology, Warsaw, Poland
| | - Andrzej Mróz
- Medical Centre for Postgraduate Education, Department of Gastroenterology, Hepatology and Clinical Oncology, Warsaw, Poland Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Department of Pathology and Laboratory Medicine, Warsaw, Poland
| |
Collapse
|